Access DB# 86690

SEARCH REQUEST FORM

Scientific and Technical Inf rmati n Center

Requester's Full Name: R Cook Examiner # : 79972 Date: 2/6/03
Art Unit: 1626 Phone Number 305 4597 Serial Number: 09/823854
Mail Box and Bldg/Room Location: 809 3D18 Results Format Preferred (circle): PAPER DISK E-MAIL

If mor than one search is submitted, please prioritize searches in order of need.

****

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: _____

Inventors (please provide full names): _____

_____

Earliest Priority Filing Date: _____

***For Sequence Searches Only* Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.**

Jan Delaval
Reference Librarian
Biotechnology & Chemical Library
CM1 1E07 – 703-308-4498
jan.delaval@uspto.gov



****

STAFF USE ONLY

Searcher: Jan
Searcher Phone #: 4198
Searcher Location: _____
Date Searcher Picked Up: 2/13/03
Date Completed: 2/13/03
Searcher Prep & Review Time: _____
Clerical Prep Time: 10
Online Time: 10

Type of Search

NA Sequence (#) _____
AA Sequence (#) _____
Structure (#) ✓
Bibliographic _____
Litigation _____
Fulltext _____
Patent Family _____
Other _____

Vendors and cost where applicable

STN ✓
Dialog _____
Questel/Orbit _____
Dr.Link _____
Lexis/Nexis _____
Sequence Systems _____
WWW/Internet _____
Other (specify) _____

PTO-1590 (8-01)

```
=> fil reg
FILE 'REGISTRY' ENTERED AT 17:19:25 ON 13 FEB 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   12 FEB 2003  HIGHEST RN 489395-53-1
DICTIONARY FILE UPDATES:  12 FEB 2003  HIGHEST RN 489395-53-1

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available.  See HELP
PROPERTIES for more information.  See STNote 27, Searching Properties
in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=> d sta que l3
L1              STR
```




```
VAR G1=2/6
VAR G2=C/S/N/O
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  30

STEREO ATTRIBUTES: NONE
L3            50 SEA FILE=REGISTRY SSS FUL L1

100.0% PROCESSED   3636 ITERATIONS                    50 ANSWERS
SEARCH TIME: 00.00.01


=> d his

     (FILE 'HOME' ENTERED AT 17:14:49 ON 13 FEB 2003)
               SET COST OFF

     FILE 'REGISTRY' ENTERED AT 17:15:07 ON 13 FEB 2003
```

```
L1              STR
L2            2 S L1
L3           50 S L1 FUL
                SAV L3 GERSTL823/A

     FILE 'HCAOLD' ENTERED AT 17:16:52 ON 13 FEB 2003
L4            0 S L3

     FILE 'HCAPLUS' ENTERED AT 17:16:59 ON 13 FEB 2003
L5            7 S L3
L6            6 S L5 AND (NELSON ? OR LEVY ? OR FRECHETTE ? OR BOWSER ? OR ISMA
L7            5 S PARATEK?/PA,CS AND L5
L8            2 S TUFTS?/PA,CS AND L5
L9            7 S L5-L8

     FILE 'USPATFULL, USPAT2' ENTERED AT 17:18:34 ON 13 FEB 2003
L10           2 S L3

     FILE 'IFIPAT' ENTERED AT 17:18:44 ON 13 FEB 2003
L11           0 S L3

     FILE 'REGISTRY' ENTERED AT 17:19:09 ON 13 FEB 2003

     FILE 'REGISTRY' ENTERED AT 17:19:25 ON 13 FEB 2003

=> fil uspatall
FILE 'USPATFULL' ENTERED AT 17:19:32 ON 13 FEB 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 17:19:32 ON 13 FEB 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

=> d l10 bib abs hitrn tot

L10  ANSWER 1 OF 2  USPATFULL
AN     97:51989  USPATFULL
TI     9-[(substituted glycyl)amido]-6-(substituted)-5-hydroxy-6-
       deoxytetracyclines
IN     Lee, Ving Jick, 19 Shuart Rd., Monsey, NY, United States  10952
       Buckwalter, Brian Lee, 102 Ovington Rd., Yardley, PA, United States
       19067
       Barden, Timothy Claude, 3424 Stafford Pl., Holland, PA, United States
       18966
PI     US 5639742              19970617
AI     US 1994-297464          19940829 (8)
RLI    Division of Ser. No. US 1993-42302, filed on 2 Apr 1993, now patented,
       Pat. No. US 5371076
DT     Utility
FS     Granted
EXNAM  Primary Examiner: Gerstl, Robert
CLMN   Number of Claims: 72
ECL    Exemplary Claim: 1
DRWN   No Drawings
LN.CNT 2551
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB     The invention provides compounds of the formula: ##STR1## wherein R,
       R.sup.1, R.sup.2 and W are defined in the specification. These compounds
       are useful as antibiotic agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT   161321-08-0P
       (prepn. of 9-[(N-substituted-glycyl)amido]-6-methyl(ene)-5-hydroxy-6-
       deoxytetracyclines as antibiotics)
```

L10 ANSWER 2 OF 2 USPATFULL
AN 94:106775 USPATFULL
TI 9-[(substituted glycyl)amido]-6-(substituted)-5-hydroxy-6-deoxytetracyclines
IN Lee, Ving J., Monsey, NY, United States
Buckwalter, Brian L., Yardley, PA, United States
Barden, Timothy C., Holland, PA, United States
PA American Cyanamid Company, Wayne, NJ, United States (U.S. corporation)
PI US 5371076 19941206
AI US 1993-42302 19930402 (8)
DT Utility
FS Granted
EXNAM Primary Examiner: Gerstl, Robert
LREP Szatkowski, Thomas S.
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2214
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides compounds of the formula: ##STR1## wherein R, R.sup.1, R.sup.2 and W are defined in the specification. These compounds are useful as antibiotic agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **161321-08-0P**
(prepn. of 9-[(N-substituted-glycyl)amido]-6-methyl(ene)-5-hydroxy-6-deoxytetracyclines as antibiotics)

=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 17:19:49 ON 13 FEB 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 13 Feb 2003 VOL 138 ISS 7
FILE LAST UPDATED: 12 Feb 2003 (20030212/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d all fhitstr tot 19

L9 ANSWER 1 OF 7 HCAPLUS COPYRIGHT 2003 ACS
AN 2003:57866 HCAPLUS
TI Tetracycline compounds having target therapeutic activities
IN **Levy, Stuart B.**; Draper, Michael; **Nelson, Mark L.**; Jones, Graham
PA **Paratek Pharmaceuticals, Inc., USA**
SO PCT Int. Appl., 158 pp.

CODEN: PIXXD2
DT Patent
LA English
ICI A61
CC 1-12 (Pharmacology)
Section cross-reference(s): 26
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003005971	A2	20030123	WO 2002-US22451	20020715

PI W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2001-305546P P 20010713

AB Methods and compds. for treating a variety of diseases with tetracycline compds. having a target therapeutic activity are described, as is compd. prepn.

ST tetracycline compd prepn therapeutic

IT Brain, disease
Prion diseases, disease
(Creutzfeldt-Jakob; tetracycline compds. with target therapeutic activities)

IT Nervous system
(GABAergic, GABAergic therapy; tetracycline compds. with target therapeutic activities, and use with other agents)

IT Brain, disease
(Gilles de la Tourette syndrome; tetracycline compds. with target therapeutic activities)

IT Nervous system
(Huntington's chorea; tetracycline compds. with target therapeutic activities)

IT Wernicke-Korsakoff syndrome
(Korsakoff's psychosis; tetracycline compds. with target therapeutic activities)

IT Amnesia
(Korsakoff's; tetracycline compds. with target therapeutic activities)

IT Glutamate antagonists
(NMDA antagonists; tetracycline compds. with target therapeutic activities, and use with other agents)

IT Inflammation
Respiratory distress syndrome
(acute; tetracycline compds. with target therapeutic activities)

IT Respiratory distress syndrome
(adult; tetracycline compds. with target therapeutic activities)

IT Nervous system
(amyotrophic lateral sclerosis; tetracycline compds. with target therapeutic activities)

IT Artery, disease
(aneurism; tetracycline compds. with target therapeutic activities)

IT Antiarteriosclerotics
(antiatherosclerotics; tetracycline compds. with target therapeutic activities)

IT Artery, disease
(aorta, aneurism; tetracycline compds. with target therapeutic activities)

IT Mental disorder

(attention deficit disorder; tetracycline compds. with target therapeutic activities)
IT Glycosylation
(biol., protein; tetracycline compds. with target therapeutic activities)
IT Bone, disease
(bone mass disorder; tetracycline compds. with target therapeutic activities)
IT Bronchi
(bronchiectasis; tetracycline compds. with target therapeutic activities)
IT Bronchi
(bronchitis; tetracycline compds. with target therapeutic activities)
IT Ion channel blockers
(calcium; tetracycline compds. with target therapeutic activities, and use with other agents)
IT Musculoskeletal diseases
(cartilage, degrdn.; tetracycline compds. with target therapeutic activities)
IT Lung, disease
(chronic obstructive; tetracycline compds. with target therapeutic activities)
IT Inflammation
Lung, disease
(chronic; tetracycline compds. with target therapeutic activities)
IT Animal cell
(compds. increasing energy available to cells; tetracycline compds. with target therapeutic activities, and use with other agents)
IT Eye, disease
(cornea, ulcer; tetracycline compds. with target therapeutic activities)
IT Antiulcer agents
(corneal ulceration; tetracycline compds. with target therapeutic activities)
IT Bone, disease
(degrdn.; tetracycline compds. with target therapeutic activities)
IT Mental disorder
(dementia, Alzheimer's disease-related; tetracycline compds. with target therapeutic activities)
IT Mental disorder
(depression, major; tetracycline compds. with target therapeutic activities)
IT Mental disorder
(depression, neurotic; tetracycline compds. with target therapeutic activities)
IT Mental disorder
(depression; tetracycline compds. with target therapeutic activities)
IT Disease, animal
(diabetic complications; tetracycline compds. with target therapeutic activities)
IT Ulcer
(diabetic; tetracycline compds. with target therapeutic activities)
IT Cartilage
(disease, degrdn.; tetracycline compds. with target therapeutic activities)
IT Nervous system
(disease; tetracycline compds. with target therapeutic activities)
IT Learning
Sleep
(disorder; tetracycline compds. with target therapeutic activities)
IT Eye, disease
(dry; tetracycline compds. with target therapeutic activities)
IT Drugs

(gastrointestinal; tetracycline compds. with target therapeutic activities)
IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(glycosylation; tetracycline compds. with target therapeutic activities)
IT Disease, animal
(inflammation process-assocd. state; tetracycline compds. with target therapeutic activities)
IT Lung, disease
(injury, acute; tetracycline compds. with target therapeutic activities)
IT Brain, disease
Nerve, disease
(injury; tetracycline compds. with target therapeutic activities)
IT Diabetes mellitus
(insulin-dependent; tetracycline compds. with target therapeutic activities)
IT Mental disorder
(mania; tetracycline compds. with target therapeutic activities)
IT Mental disorder
(manic bipolar disorder; tetracycline compds. with target therapeutic activities)
IT Neoplasm
(metastasis; tetracycline compds. with target therapeutic activities)
IT Headache
(migraine; tetracycline compds. with target therapeutic activities)
IT Nerve, disease
(motor; tetracycline compds. with target therapeutic activities)
IT Nerve
(neuron, neuronal membrane stabilizers; tetracycline compds. with target therapeutic activities, and use with other agents)
IT Membrane, biological
(neuronal membrane stabilizers; tetracycline compds. with target therapeutic activities, and use with other agents)
IT Cytoprotective agents
(neuroprotectants; tetracycline compds. with target therapeutic activities, and use with other agents)
IT Mental disorder
(obsession-compulsion; tetracycline compds. with target therapeutic activities)
IT Bone, neoplasm
(osteosarcoma; tetracycline compds. with target therapeutic activities)
IT Anxiety
(panic disorder; tetracycline compds. with target therapeutic activities)
IT Periodontium
(periodontitis; tetracycline compds. with target therapeutic activities)
IT Mental disorder
(phobia; tetracycline compds. with target therapeutic activities)
IT Fatty acids
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(polyunsatd., n-3; tetracycline compds. with target therapeutic activities, and use with other agents)
IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(protein buildup removal agents; tetracycline compds. with target therapeutic activities, and use with other agents)
IT Paralysis
(pseudobulbar; tetracycline compds. with target therapeutic activities)
IT Transcription, genetic

(regulators; tetracycline compds. with target therapeutic activities, and use with other agents)

IT Artery, disease
(restenosis; tetracycline compds. with target therapeutic activities)

IT Mental disorder
(schizoaffective disorder; tetracycline compds. with target therapeutic activities)

IT Mental disorder
(senile psychosis; tetracycline compds. with target therapeutic activities)

IT Respiratory tract
(sinusitis; tetracycline compds. with target therapeutic activities)

IT Ion channel blockers
(sodium; tetracycline compds. with target therapeutic activities, and use with other agents)

IT Brain, disease
(stroke; tetracycline compds. with target therapeutic activities)

IT Aging, animal
Alzheimer's disease
Amnesia
Aneurysm
Angiogenesis
Angiogenesis inhibitors
Anti-Alzheimer's agents
Anti-inflammatory agents
Anti-ischemic agents
Antiarteriosclerotics
Antiarthritics
Antiasthmatics
Antibacterial agents
Anticonvulsants
Antidepressants
Antidiabetic agents
Antihypertensives
Antimalarials
Antimigraine agents
Antipsychotics
Antirheumatic agents
Antitumor agents
Antiviral agents
Anxiety
Anxiolytics
Arteriosclerosis
Asthma
Atherosclerosis
Autoimmune disease
Carcinoma
Cardiovascular agents
Cognition enhancers
Cystic fibrosis
Diabetes mellitus
Drug delivery systems
Emphysema
Epilepsy
Escherichia coli
Eye, disease
Fungicides
Hepatitis
Human
Hypertension
Inflammation
Ischemia
Lung, disease

Macrophage
Malaria
Mental disorder
Multiple sclerosis
Neoplasm
Nervous system agents
Osteoarthritis
Osteomyelitis
Osteoporosis
Parasiticides
Psychotropics
Rheumatoid arthritis
Sarcoma
Schizophrenia
Skin, disease
Staphylococcus aureus
Wound healing promoters
(tetracycline compds. with target therapeutic activities)

IT Tetracyclines
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tetracycline compds. with target therapeutic activities)

IT Anti-infective agents
Antioxidants
Chemotherapy
Ginkgo biloba
Opioid antagonists
Radiotherapy
(tetracycline compds. with target therapeutic activities, and use with other agents)

IT Glucocorticoids
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tetracycline compds. with target therapeutic activities, and use with other agents)

IT Wound
(tissue; tetracycline compds. with target therapeutic activities)

IT Brain, disease
Spinal cord
(trauma; tetracycline compds. with target therapeutic activities)

IT Intestine, disease
(ulcerative colitis; tetracycline compds. with target therapeutic activities)

IT Blood vessel, disease
(vascular stroke; tetracycline compds. with target therapeutic activities)

IT Tumor necrosis factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(.alpha., antagonists; tetracycline compds. with target therapeutic activities, and use with other agents)

IT 141907-41-7, Matrix metalloproteinase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(MMP-4 and MMP5, inflammatory process-assocd. state assocd. with; tetracycline compds. with target therapeutic activities)

IT 10102-43-9, Nitric oxide
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(NO-assocd. state; tetracycline compds. with target therapeutic activities)

IT 56-86-0, L-Glutamic acid
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(anti-glutamate therapy; tetracycline compds. with target therapeutic activities, and use with other agents)

IT 9001-12-1, matrix metalloproteinase 1 9004-06-2, matrix

metalloproteinase 12 79955-99-0, matrix metalloproteinase 3
140610-48-6, matrix metalloproteinase 10 141256-52-2, matrix
metalloproteinase 7 145267-01-2, matrix metalloproteinase 11
146480-35-5, matrix metalloproteinase 2 146480-36-6, matrix
metalloproteinase 9 161384-17-4, matrix metalloproteinase 14
172308-17-7, matrix metalloproteinase 15 175449-82-8, matrix
metalloproteinase 13 182970-56-5, matrix metalloproteinase 16
185766-51-2, matrix metalloproteinase 20 188364-80-9, matrix
metalloproteinase 19 203810-08-6, matrix metalloproteinase 17
252351-86-3, matrix metalloproteinase 6
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inflammatory process-assocd. state assocd. with; tetracycline compds.
with target therapeutic activities)

IT 9001-08-5, Cholinesterase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; tetracycline compds. with target therapeutic activities,
and use with other agents)

IT 389624-49-1P 488820-35-5P 488820-36-6P 488820-38-8P 488820-39-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(tetracycline compds. with target therapeutic activities)

IT 60-54-8 60-54-8D, Tetracycline, derivs. 127-33-3 564-25-0 914-00-1
2444-65-7 3242-03-3 4497-07-8 5874-95-3 5995-55-1 10118-89-5
16145-05-4 24290-70-8 31642-30-5 35689-63-5 35689-65-7
53108-41-1 53173-80-1 59046-79-6 77901-56-5 115207-75-5
120793-45-5 146253-71-6 146253-75-0 146278-01-5 146278-02-6
146278-03-7 149934-16-7 149934-19-0 151922-17-7 153621-68-2
161320-33-8 161321-34-2 161452-36-4 186759-47-7 186759-49-9
186759-51-3 186759-53-5 186759-55-7 186759-61-5 220620-09-7
233585-94-9 233585-95-0 233585-96-1 233585-97-2 233586-02-2
233586-03-3 233586-04-4 233586-06-6 233586-07-7 233586-08-8
233586-09-9 233586-10-2 233586-11-3 233586-12-4 233586-16-8
263760-96-9 263760-98-1 263761-01-9 263761-02-0 263761-08-6
295356-11-5 295356-12-6 295356-13-7 295356-16-0 295356-17-1
330627-21-9 330627-22-0 330627-23-1 330627-24-2 330627-26-4
330627-27-5 330627-32-2 344771-54-6 351336-92-0 351336-94-2
365276-98-8 365276-99-9 365277-00-5 365277-01-6 365277-02-7
365277-03-8 365277-04-9 365277-05-0 365277-06-1 365277-08-3
365277-11-8 365277-12-9 365277-13-0
365277-14-1 365277-16-3 365277-19-6 365277-20-9
365277-21-0 365277-22-1 365277-23-2 365277-24-3 365277-26-5
365277-28-7 365277-29-8 365277-34-5 365277-35-6 365277-36-7
365277-37-8 365277-38-9 **365277-39-0 365277-40-3**
365277-41-4 365277-42-5 365277-43-6
365277-44-7 365277-45-8 365277-46-9 365277-47-0 365277-48-1
365277-49-2 365277-50-5 365277-51-6 365277-52-7 365277-53-8
365277-54-9 365277-55-0 365277-56-1 365277-57-2 365277-58-3
365277-59-4 365277-60-7 365277-61-8 365277-62-9 365277-63-0
365277-64-1 365277-65-2 **365277-66-3 365277-88-9**
374748-06-8 380435-62-1 380435-63-2 380435-65-4 380435-76-7
380435-88-1 389081-55-4 389081-56-5 389081-58-7 389081-60-1
389081-61-2 389081-62-3 389081-63-4 389081-64-5 389081-65-6
389081-66-7 389081-67-8 389081-68-9 389081-69-0 389081-71-4
389081-72-5 389081-73-6 389081-74-7 389081-75-8 389081-76-9
389081-77-0 389081-78-1 389081-79-2 389081-80-5 389081-85-0
389139-10-0 389139-12-2 389139-15-5 389139-16-6 389139-17-7
389139-18-8 389139-19-9 389139-20-2 389139-21-3 389139-22-4
389139-23-5 389139-24-6 389139-25-7 389139-26-8 389139-27-9
389139-28-0 389139-29-1 389139-31-5 389139-32-6 389139-33-7
389139-34-8 389139-35-9 389139-36-0 389139-37-1 389139-38-2
389139-39-3 389139-40-6 389139-41-7 389139-42-8 389139-43-9
389139-44-0 389139-45-1 389139-46-2 389139-47-3 389139-48-4

389139-49-5 389139-51-9 389139-52-0 389139-53-1 389139-54-2
389139-55-3 389139-56-4 389139-57-5 389139-58-6 389139-59-7
389139-60-0 389139-61-1 389139-62-2 389139-63-3 389139-64-4
389139-65-5 389139-66-6 389139-67-7 389139-68-8 389139-69-9
389139-70-2 389139-71-3 389139-72-4 389139-73-5 389139-74-6
389139-75-7 389139-78-0 389139-79-1 389139-80-4 389139-81-5
389139-82-6 389139-83-7 389139-85-9 389139-86-0 389139-87-1
389139-88-2 389139-89-3 389139-90-6
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tetracycline compds. with target therapeutic activities)

IT 389139-91-7 389139-92-8 389139-93-9 389139-94-0 389139-95-1
389139-96-2 389139-97-3 389139-98-4 389139-99-5 389140-00-5
389140-01-6 389140-02-7 389140-03-8 389140-04-9 389140-06-1
389570-43-8 389570-46-1 389570-49-4 389570-50-7 389570-51-8
389570-52-9 389570-53-0 389570-54-1 389623-72-7 389623-77-2
389623-80-7 389623-82-9 389623-86-3 389623-88-5 389623-89-6
389623-91-0 389623-93-2 389623-95-4 389623-96-5 389623-97-6
389623-98-7 389623-99-8 389624-01-5 389624-02-6 389624-03-7
389624-04-8 389624-05-9 389624-08-2 389624-09-3 389624-12-8
389624-13-9 389624-14-0 389624-15-1 389624-18-4 389624-20-8
389624-21-9 389624-22-0 389624-23-1 389624-24-2 389624-26-4
389624-27-5 389624-28-6 389624-29-7 389624-30-0 389624-31-1
389624-32-2 389624-33-3 389624-34-4 389624-35-5 389624-36-6
389624-37-7 389624-38-8 389624-39-9 389624-40-2 389624-41-3
389624-43-5 389624-44-6 389624-45-7 389624-46-8 389624-51-5
389624-52-6 389624-54-8 389624-55-9 389624-56-0 389624-57-1
389624-59-3 389624-62-8 389624-63-9 389624-66-2 389624-67-3
389624-68-4 389624-69-5 389624-70-8 389624-71-9 389624-72-0
389624-73-1 389624-75-3 389624-76-4 389624-77-5 389624-78-6
389624-79-7 389624-80-0 389624-81-1 389624-82-2 389624-83-3
389624-84-4 389624-85-5 389624-86-6 389624-87-7 389624-88-8
389624-89-9 389624-90-2 389624-91-3 389624-92-4 389624-93-5
389624-94-6 389624-95-7 389624-97-9 389624-98-0 389624-99-1
389625-00-7 389625-01-8 389625-02-9 389625-03-0 389625-04-1
389625-05-2 389625-06-3 389625-07-4 389625-09-6 389625-10-9
389625-11-0 389625-12-1 439217-57-9 439217-59-1 459425-79-7
459425-80-0 459425-96-8 459426-11-0 459809-42-8 459809-43-9
459809-44-0 459809-45-1 459809-46-2 459809-47-3 459809-48-4
459809-49-5 459809-50-8 459809-51-9 459809-52-0 459809-53-1
459809-54-2 459809-55-3 459809-56-4 459809-57-5 459809-58-6
459809-59-7 459809-61-1 459809-63-3 459809-65-5 459809-66-6
459809-67-7 459809-68-8 459809-70-2 459809-72-4 459809-74-6
459809-76-8 459809-77-9 459809-79-1 459809-81-5 459809-82-6
459809-86-0 459809-88-2 459809-91-7 459809-92-8 459809-93-9
459809-94-0 459809-95-1 459809-96-2 459809-97-3 459809-98-4
459810-00-5 459810-01-6 459810-02-7 459810-03-8 459810-04-9
459810-06-1 459810-07-2 459810-09-4 460068-26-2 460068-27-3
460068-29-5 460068-30-8 460068-31-9 460068-33-1 460068-34-2
460068-35-3 460068-36-4 460068-38-6 460068-39-7 460068-40-0
460068-41-1 460068-43-3 460068-44-4 460068-45-5 460068-46-6
460068-47-7 460068-48-8 460068-49-9 460068-50-2 460068-51-3
460068-52-4 460068-53-5 460068-54-6 460068-55-7 460068-57-9
460068-58-0 460068-59-1 460068-60-4 460068-63-7 460068-64-8
460068-65-9 460068-66-0 460068-67-1 460068-68-2 460068-69-3
460068-70-6 460068-71-7 460068-72-8 460068-73-9 460068-74-0
460068-75-1 460068-76-2 460068-77-3 460068-78-4 460068-79-5
460068-80-8 460068-81-9 460068-82-0 460068-83-1 460068-84-2
460068-85-3 460068-86-4
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tetracycline compds. with target therapeutic activities)

IT 460068-87-5 460068-88-6 460068-90-0 460068-92-2 **460068-93-3**

460068-94-4 460068-95-5 460068-96-6 460068-97-7
460068-99-9 460069-34-5 460069-38-9 460069-65-2 460069-70-9
460069-89-0 460069-96-9 460070-02-4 460070-03-5 460070-53-5
460070-61-5 460070-66-0 460070-73-9 460070-76-2 460070-79-5
460070-92-2 460070-95-5 460071-02-7 460071-04-9 460071-06-1
460071-09-4 460071-12-9 460071-14-1 460071-17-4 460071-19-6
460071-29-8 460071-31-2 460071-33-4 460071-37-8 460071-66-3
460071-69-6 460071-80-1 460071-83-4 460071-87-8 460071-89-0
460071-91-4 460071-93-6 460071-97-0 460071-99-2 460072-01-9
460072-03-1 460072-05-3 460072-07-5 460072-09-7 460072-10-0
460072-12-2 460072-15-5 460072-17-7 460072-19-9 460072-21-3
460072-25-7 460072-28-0 460072-29-1 460072-30-4 460072-31-5
460072-33-7 460072-36-0 460072-38-2 460072-40-6 460072-43-9
460072-45-1 460072-47-3 460072-49-5 460072-61-1 460072-63-3
460072-65-5 460072-70-2 460072-73-5 460072-75-7 460072-78-0
460072-82-6 460072-86-0 460072-89-3 460072-91-7 460072-93-9
460072-99-5 460073-01-2 460073-03-4 460073-05-6 460073-07-8
460073-09-0 460073-11-4 460073-15-8 460073-17-0 460073-21-6
460073-22-7 460073-23-8 460073-25-0 460073-27-2 460073-29-4
460073-31-8 460073-33-0 460073-35-2 460073-37-4 460073-40-9
460073-41-0 460073-43-2 **460073-45-4** 460073-47-6
460073-49-8 460073-51-2 **460073-55-6** 460073-58-9
460073-60-3 460073-62-5 460073-64-7 460073-68-1 460073-70-5
460073-72-7 460073-74-9 **460073-76-1** 460073-78-3
460073-80-7 460073-82-9 460073-84-1 460073-86-3 460073-88-5
460073-90-9 460073-92-1 460073-94-3 460073-96-5 460074-00-4
460074-02-6 460074-04-8 460074-06-0 460074-11-7 460074-13-9
460074-17-3 460074-19-5 460074-21-9 460074-23-1 460074-26-4
460074-28-6 460074-30-0 460074-32-2 460074-34-4 460074-36-6
460074-38-8 460074-40-2 460074-42-4 460074-44-6 460074-46-8
460074-48-0 460074-50-4 460074-52-6 460074-54-8 460074-56-0
460074-58-2 460074-60-6 460074-62-8 460074-64-0 460074-66-2
460074-68-4 460074-69-5 460074-71-9 460074-73-1 460074-75-3
460074-77-5 460074-79-7 460074-81-1 460074-85-5 460074-87-7
460074-89-9 460074-91-3 460074-93-5 460074-95-7 460074-97-9
460074-99-1 460075-04-1 460075-06-3 460075-08-5 460075-12-1
460075-14-3 460075-62-1 460076-23-7 460082-87-5 **460082-89-7**
460082-90-0 473973-13-6 473973-20-5 473973-34-1 473973-37-4
473973-41-0 473973-62-5 473973-64-7 473973-86-3 473973-96-5
473974-12-8 473974-75-3 473974-76-4 473974-77-5 473974-79-7
473974-80-0 473974-81-1 473974-82-2 473974-83-3 473974-84-4
473974-85-5 488815-44-7 488815-45-8 488815-46-9 488815-47-0
488815-48-1 488815-49-2 488815-50-5 488815-51-6 488815-52-7
488815-53-8 488815-54-9 488815-55-0 488815-56-1 488815-57-2
488815-58-3 488815-59-4 488815-60-7 488815-61-8 488815-62-9
488815-63-0 488815-64-1 488815-65-2 488815-66-3 488815-67-4
488815-68-5 488815-69-6 488815-70-9 488815-71-0 488815-72-1
488815-73-2
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tetracycline compds. with target therapeutic activities)

IT 488815-74-3 488815-75-4 488815-76-5 488815-77-6 488815-78-7
488815-79-8 488815-80-1 488815-82-3 488815-89-0 488815-93-6
488815-98-1 488816-00-8 488816-09-7 488816-13-3 488816-16-6
488816-18-8 488816-19-9 488816-26-8 488816-37-1 488816-39-3
488816-42-8 488816-54-2 488816-55-3 488816-58-6 488816-59-7
488816-64-4 488816-65-5 488816-70-2 488816-71-3 488816-73-5
488816-75-7 488816-82-6 488816-86-0 488816-88-2 488816-92-8
488816-93-9 488816-98-4 488817-01-2 488817-06-7 488817-11-4
488817-13-6 488817-14-7 488817-15-8 488817-16-9 488817-17-0
488817-18-1 488817-19-2 488817-20-5 488817-21-6 488817-22-7
488817-23-8 488817-24-9 488817-25-0 488817-26-1 488817-27-2
488817-28-3 488817-29-4 488817-30-7 488817-31-8 488817-32-9

488817-33-0 **488817-34-1** 488817-35-2 488817-36-3
488817-37-4 488817-38-5 488817-39-6 488817-40-9 488817-41-0
488817-42-1 488817-43-2 488817-44-3 488817-45-4 488817-46-5
488817-47-6 488817-48-7 488817-49-8 488817-50-1 488817-51-2
488817-52-3 488817-53-4 488817-54-5 488817-55-6 488817-56-7
488817-57-8 488817-58-9 488817-59-0 488817-60-3 488817-61-4
488817-62-5 488817-63-6 488817-64-7 488817-65-8 488817-66-9
488817-67-0 488817-68-1 488817-69-2 488817-70-5 488817-71-6
488817-72-7 488817-73-8 488817-74-9 488817-75-0 488817-76-1
488817-77-2 488817-78-3 488817-79-4 488817-80-7 488817-81-8
488817-82-9 488817-89-6 488817-91-0 488817-92-1 488817-93-2
488817-94-3 488817-95-4 488817-96-5 488817-97-6 488817-98-7
488817-99-8 488818-00-4 488818-01-5 488818-02-6 488818-03-7
488818-04-8 488818-05-9 488818-06-0 488818-07-1 488818-08-2
488818-09-3 488818-10-6 488818-11-7 488818-12-8 488818-13-9
488818-14-0 **488818-15-1** 488818-16-2 488818-17-3
488818-18-4 488818-19-5 488818-20-8 488818-21-9 **488818-22-0**
488818-23-1 **488818-24-2** 488818-25-3 488818-26-4
488818-27-5 488818-28-6 **488818-29-7** 488818-30-0
488818-31-1 488818-32-2 **488818-33-3** 488818-34-4
488818-35-5 **488818-36-6** 488818-37-7 488818-38-8
488818-39-9 488818-40-2 488818-41-3 488818-42-4
488818-43-5 488818-44-6 488818-45-7 488818-46-8 488818-47-9
488818-48-0 **488818-49-1** 488818-50-4 488818-51-5
488818-52-6 488818-53-7 488818-54-8 488818-55-9 488818-56-0
488818-57-1 488818-58-2 488818-59-3 488818-60-6 488818-61-7
488818-62-8 488818-63-9 488818-64-0 488818-65-1 488818-66-2
488818-67-3 488818-68-4 488818-69-5 488818-70-8 488818-71-9
488818-72-0 488818-73-1 488818-74-2 488818-75-3 488818-76-4
488818-77-5 488818-78-6 488818-79-7 488818-80-0 488818-81-1
488818-82-2 488818-83-3 488818-84-4 488818-85-5 488818-86-6
488818-87-7 488818-88-8 488818-89-9 488818-90-2 488818-91-3
488818-92-4 488818-93-5 488818-94-6 488818-95-7 488818-96-8
488818-97-9 488818-98-0 488818-99-1 488819-00-7 488819-01-8
488819-02-9 488819-03-0 488819-04-1 488819-05-2 488819-06-3
488819-07-4 488819-08-5 488819-14-3 488819-15-4 488819-16-5
488819-17-6 488819-18-7 488819-19-8 488819-20-1 488819-21-2
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tetracycline compds. with target therapeutic activities)

IT 488819-22-3 **488819-23-4** 488819-24-5 488819-25-6
488819-26-7 488819-27-8 488819-28-9 488819-29-0 488819-30-3
488819-31-4 488819-32-5 488819-33-6 488819-34-7 488819-35-8
488819-36-9 488819-37-0 488819-38-1 488819-39-2 488819-40-5
488819-41-6 488819-42-7 488819-43-8 488819-44-9 488819-45-0
488819-46-1 488819-47-2 488819-48-3 488819-49-4 488819-50-7
488819-51-8 488819-52-9 488819-53-0 488819-54-1 488819-55-2
488819-56-3 488819-57-4 488819-58-5 488819-59-6 488819-60-9
488819-61-0 488819-62-1 488819-63-2 488819-64-3 488819-65-4
488819-66-5 488819-67-6 488819-68-7 488819-69-8 488819-70-1
488819-71-2 488819-72-3 488819-73-4 488819-74-5 488819-75-6
488819-76-7 488819-77-8 488819-78-9 488819-79-0 488819-80-3
488819-81-4 488819-82-5 488819-83-6 488819-84-7 488819-85-8
488819-86-9 488819-87-0 488819-88-1 488819-89-2 488819-90-5
488819-91-6 488819-92-7 488819-93-8 488819-94-9 488819-95-0
488819-96-1 488819-97-2 488819-98-3 488819-99-4 488820-00-4
488820-01-5 488820-02-6 488820-03-7 488820-04-8 488820-05-9
488820-06-0 488820-07-1 488820-08-2 488820-09-3 488820-10-6
488820-11-7 488820-12-8 488820-13-9 488820-14-0 488820-15-1
488820-16-2 488820-17-3 488820-18-4 488820-19-5 488820-20-8
488820-21-9 488820-22-0 488820-23-1 488820-24-2 488820-25-3
488820-26-4 488820-27-5 488820-28-6 488820-29-7 488820-30-0
488820-31-1 488820-32-2 488820-33-3 488820-34-4 488820-42-4

488820-43-5 488820-44-6 488820-45-7 488820-46-8 488820-47-9
488820-48-0 488820-49-1 488820-50-4 488821-84-7
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tetracycline compds. with target therapeutic activities)

IT 74-99-7, Propyne 100-39-0, Benzyl bromide 103-55-9 111-30-8, Glutaraldehyde 122-78-1, Phenylacetaldehyde 622-77-5, Benzylcyanamide 808-26-4, Sancycline 871-84-1, 1,7-Octadiyne 5371-49-3 13614-98-7, Minocycline hydrochloride 25154-38-5, Piperazineethanol 25267-27-0, Iodobutane 50696-61-2, Cyclohexenylacetylene 55552-70-0, 3-Furanyl boronic acid 107099-99-0, 2,5-Dimethoxyphenyl boronic acid 128796-39-4, 4-Trifluoromethylphenyl boronic acid 144025-03-6, 2,4-Difluorophenyl boronic acid 149104-90-5, 4-Acetylphenylboronic acid 389625-14-3 460076-35-1 460076-38-4 488820-37-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(tetracycline compds. with target therapeutic activities)

IT 113164-67-3P, 7-Iodosancycline
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(tetracycline compds. with target therapeutic activities)

IT 50-81-7, vitamin C 53-03-2, Prednisone 302-79-4, Retinoic acid 303-98-0, coenzyme Q10 987-78-0, CDP-choline 1134-47-0, Baclofen 1406-18-4, vitamin E 1744-22-5, Riluzole 2763-96-4, Muscimol 7782-49-2, Selenium 10118-90-8, Minocycline 11096-26-7, Erythropoietin 11103-57-4, vitamin A 14611-51-9, Selegiline 57828-26-9, Lipoic acid 60142-96-3, Gabapentin 84057-84-1, Lamotrigine 112924-45-5, Dexanabinol 128298-28-2, Remacemide
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tetracycline compds. with target therapeutic activities, and use with other agents)

IT **365277-11-8**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(tetracycline compds. with target therapeutic activities)

RN 365277-11-8 HCAPLUS
CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-9-[(4-ethyl-2-thiazolyl)amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aR,5S,5aR,6R,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L9 ANSWER 2 OF 7 HCAPLUS COPYRIGHT 2003 ACS
AN 2002:832571 HCAPLUS
DN 137:333118
TI Substituted tetracycline compounds for the treatment of malaria
IN Draper, Michael; **Nelson, Mark L.**; **Frechette, Roger**
PA **Paratek Pharmaceuticals, Inc., USA**
SO PCT Int. Appl., 89 pp.
CODEN: PIXXD2
DT Patent

LA English
IC ICM A61K
CC 1-5 (Pharmacology)
Section cross-reference(s): 25, 63
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002085303	A2	20021031	WO 2002-US12935	20020424

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2001-286193P P 20010424
OS MARPAT 137:333118
AB The invention provides a method for treating or preventing malaria in a subject. The method includes administering to the subject an effective amt. of a substituted tetracycline compd., such that malaria is treated or prevented. In one aspect, the invention provides pharmaceutical compns. which include an effective amt. of a tetracycline compd. to treat malaria in a subject and a pharmaceutically acceptable carrier. The substituted tetracycline compds. of the invention can be used in combination with one or more antimalarial compds. or can be used to treat or prevent malaria which is resistant to one or more other antimalarial compds. Compd. prepn. is described.
ST tetracycline deriv prepn antimalarial; malaria treatment tetracycline deriv
IT Antimalarials
Drug resistance
Malaria
Plasmodium falciparum
Plasmodium malariae
Plasmodium ovale
Plasmodium vivax
(Substituted tetracycline compds. for the treatment of malaria)
IT Sulfonamides
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(Substituted tetracycline compds. for the treatment of malaria)
IT Headache
(and malaise, supplementary compd. for treatment of; Substituted tetracycline compds. for the treatment of malaria)
IT Antimicrobial agents
(antimicrobial Gram-pos. activity; Substituted tetracycline compds. for the treatment of malaria)
IT Drug delivery systems
(prodrugs; Substituted tetracycline compds. for the treatment of malaria)
IT Spleen, disease
(splenomegaly, supplementary compd. for treatment of; Substituted tetracycline compds. for the treatment of malaria)
IT Anemia (disease)
Fever and Hyperthermia
(supplementary compd. for treatment of; Substituted tetracycline compds. for the treatment of malaria)
IT Antipyretics
(supplementary compd.; Substituted tetracycline compds. for the treatment of malaria)
IT Drug delivery systems
(tetracycline derivs. for malaria treatment)

IT 58-14-0, Pyrimethamine
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(Substituted tetracycline compds. for the treatment of malaria)

IT 54-05-7, Chloroquine 56-54-2, Quinidine 86-42-0, Amodiaquine 90-34-6, Primaquine 130-95-0, Quinine 500-92-5, Proguanil 537-21-3, Chlorproguanil 550-81-2, Amopyroquine 738-70-5, Trimethoprim 37338-39-9 37357-69-0 53230-10-7, Mefloquine 63968-64-9, Artemisinin 69756-53-2, Halofantrine 71963-77-4, Artemether 74847-35-1, Pyronaridine 82186-77-4, Lumefantrine 88495-63-0, Artesunate 95233-18-4, Atovaquone 123407-36-3, Arteflene
RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Substituted tetracycline compds. for the treatment of malaria)

IT 389139-31-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(Substituted tetracycline compds. for the treatment of malaria)

IT 60-54-8 60-54-8D, Tetracycline, derivs. 79-57-2 127-33-3 564-25-0 808-26-4 914-00-1 10118-90-8 31642-30-5 35689-65-7 146253-75-0 146278-03-7 151922-17-7 186759-47-7 186759-51-3 186759-53-5 201849-42-5 233585-95-0 233586-04-4 233586-06-6 233586-09-9 263760-98-1 263761-02-0 263761-08-6 330627-24-2 344771-54-6 351336-94-2 365277-01-6 365277-22-1 365277-23-2 365277-28-7 365277-29-8 365277-38-9 365277-45-8 365277-47-0 365277-51-6 365277-55-0 365277-56-1 365277-57-2 365277-59-4 365277-60-7 365277-63-0 **365277-66-3** 374748-06-8 380435-62-1 380435-63-2 380435-65-4 380435-76-7 389081-56-5 389081-58-7 389081-61-2 389081-62-3 389081-64-5 389081-77-0 389081-85-0 389139-10-0 389139-12-2 389139-16-6 389139-19-9 389139-20-2 389139-21-3 389139-22-4 389139-23-5 389139-24-6 389139-27-9 389139-28-0 389139-30-4 389139-33-7 389139-41-7 389139-43-9 389139-44-0 389139-45-1 389139-46-2 389139-48-4 389139-49-5 389139-50-8 389139-51-9 389139-52-0 389139-53-1 389139-54-2 389139-55-3 389139-58-6 389139-62-2 389139-63-3 389139-64-4 389139-65-5 389139-67-7 389139-68-8 389139-78-0 389139-81-5 389139-86-0 389139-91-7 389139-93-9 389140-00-5 389623-72-7 389623-77-2 389623-80-7 389623-82-9 389623-88-5 389623-89-6 389623-90-9 389623-91-0 389623-93-2 389623-95-4 389623-96-5 389623-97-6 389623-99-8 389624-00-4 389624-01-5 389624-02-6 389624-03-7 389624-04-8 389624-05-9 389624-06-0 389624-07-1 389624-08-2 389624-09-3 389624-10-6 389624-11-7 389624-12-8 389624-14-0 389624-15-1 389624-16-2 389624-18-4 389624-19-5 389624-20-8 389624-21-9 389624-22-0 389624-23-1 389624-24-2 389624-26-4 389624-27-5 389624-28-6 389624-30-0 389624-32-2 389624-33-3 389624-35-5 389624-36-6 389624-37-7 389624-38-8 389624-39-9 389624-40-2 389624-41-3 389624-42-4 389624-43-5 389624-51-5 389624-55-9 389624-62-8 389624-73-1 389624-74-2 389624-75-3 389624-81-1 389624-83-3 389624-85-5 389624-95-7 389624-96-8 389624-97-9 389624-99-1 459809-44-0 459809-46-2 459809-53-1 459809-67-7 459809-72-4 459809-99-5 459810-00-5 459810-03-8 459810-06-1 460068-29-5 460068-31-9 460068-32-0 460068-33-1 460068-36-4 460068-38-6 460068-42-2 460068-44-4 460068-45-5 460068-48-8 460068-51-3 460068-55-7 460068-57-9 460068-58-0 460068-59-1 460068-60-4 460068-62-6 460068-65-9 460068-66-0 460068-68-2 460068-76-2 460068-77-3 460068-78-4 460068-80-8 460068-86-4 460068-87-5 **460068-93-3** 460068-95-5 460068-96-6 460068-97-7 460069-34-5 460069-38-9 460069-65-2 460069-70-9 460069-96-9 460070-02-4 460070-03-5 460070-61-5 460070-66-0 460070-73-9 460070-95-5 460071-09-4 460071-12-9 460071-14-1 460071-33-4 460072-33-7 460072-47-3 460072-59-7 460072-65-5 460073-05-6 460073-17-0 460073-22-7 460074-06-0 460074-13-9 460074-19-5 460074-21-9 460075-62-1

460082-77-3 **460082-89-7** 473972-91-7 473973-13-6
473973-20-5 473973-34-1 473973-37-4 473973-41-0 473973-62-5
473973-64-7 473973-69-2 473973-86-3 473973-96-5
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Substituted tetracycline compds. for the treatment of malaria)

IT 473974-12-8 473974-75-3 473974-76-4 473974-77-5 473974-79-7
473974-80-0 473974-81-1 473974-82-2 473974-83-3 473974-84-4
473974-85-5
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Substituted tetracycline compds. for the treatment of malaria)

IT 263760-96-9P, 7-Phenylsancycline 263760-99-2P 389140-02-7P
389623-67-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(tetracycline derivs. for malaria treatment)

IT 98-80-6, Phenylboronic acid 1679-18-1, 4-Chlorophenylboronic acid
1765-93-1, 4-Fluorophenylboronic acid 14047-29-1, p-Carboxyphenylboronic acid 35037-73-1, 4-Trifluoromethoxyphenylisocyanate 59046-78-5
263761-01-9 389140-05-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(tetracycline derivs. for malaria treatment)

IT 113164-67-3P, 7-Iodosancycline 389140-04-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(tetracycline derivs. for malaria treatment)

IT **365277-66-3**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Substituted tetracycline compds. for the treatment of malaria)

RN 365277-66-3 HCAPLUS
CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-9-[(4-phenyl-2-thiazolyl)amino]-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L9 ANSWER 3 OF 7 HCAPLUS COPYRIGHT 2003 ACS
AN 2002:716035 HCAPLUS
DN 137:244598
TI Substituted tetracycline compounds as synergistic antifungal agents
IN Draper, Michael; **Nelson, Mark L.**
PA **Paratek Pharmaceuticals, Inc., USA**
SO PCT Int. Appl., 114 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K
CC 10-5 (Microbial, Algal, and Fungal Biochemistry)

Section cross-reference(s): 1, 5, 26

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002072031	A2	20020919	WO 2002-US7829	20020314

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2001-275899P P 20010314

OS MARPAT 137:244598

AB Methods and compns. for treating for the synergistic treatment of fungal assocd. disorders are discussed. The method includes administering the antifungal agent with an effective amt. of a substituted tetracycline compd., such that the antifungal activity of the antifungal agent is increased. Examples of antifungal agents include polyenes such as amphotericin B.

ST tetracycline synergistic antifungal agent

IT Actinomyces
(actinomycosis from; substituted tetracycline compds. as synergistic antifungal agents in relation to cytotoxicity)

IT Aspergillus
(aspergillosis from; substituted tetracycline compds. as synergistic antifungal agents in relation to cytotoxicity)

IT Blastomyces
Mycosis
(blastomycosis, North American; substituted tetracycline compds. as synergistic antifungal agents in relation to cytotoxicity)

IT Blastomyces
Mycosis
(blastomycosis; substituted tetracycline compds. as synergistic antifungal agents in relation to cytotoxicity)

IT Candida albicans
(candidiasis from; substituted tetracycline compds. as synergistic antifungal agents in relation to cytotoxicity)

IT Drug delivery systems
(carriers; substituted tetracycline compds. as synergistic antifungal agents in relation to cytotoxicity)

IT Skin, disease
(chromoblastomycosis; substituted tetracycline compds. as synergistic antifungal agents in relation to cytotoxicity)

IT Mycosis
(coccidioidomycosis; substituted tetracycline compds. as synergistic antifungal agents in relation to cytotoxicity)

IT Tinea (skin disease)
(cruris; substituted tetracycline compds. as synergistic antifungal agents in relation to cytotoxicity)

IT Cryptococcus neoformans
(cryptococcosis from; substituted tetracycline compds. as synergistic antifungal agents in relation to cytotoxicity)

IT Lymphatic system
(disease, epizootic lymphangitis; substituted tetracycline compds. as synergistic antifungal agents in relation to cytotoxicity)

IT Toxicity
(drug, immunosuppression from, fungal infections in; substituted tetracycline compds. as synergistic antifungal agents in relation to cytotoxicity)

IT Entomophthorales

(entomophthoromycosis from; substituted tetracycline compds. as synergistic antifungal agents in relation to cytotoxicity)
IT Histoplasma farciminosum
(epizootic lymphangitis from; substituted tetracycline compds. as synergistic antifungal agents in relation to cytotoxicity)
IT Immunosuppression
(from chemotherapy, fungal infections in; substituted tetracycline compds. as synergistic antifungal agents in relation to cytotoxicity)
IT AIDS (disease)
Immunodeficiency
(fungal infections in; substituted tetracycline compds. as synergistic antifungal agents in relation to cytotoxicity)
IT Disease, plant
(fungal; substituted tetracycline compds. as synergistic antifungal agents in relation to cytotoxicity)
IT Geotrichum candidum
(geotrichosis from; substituted tetracycline compds. as synergistic antifungal agents in relation to cytotoxicity)
IT Chemotherapy
(immunosuppression from, fungal infections in; substituted tetracycline compds. as synergistic antifungal agents in relation to cytotoxicity)
IT Histoplasma capsulatum
(infection with; substituted tetracycline compds. as synergistic antifungal agents in relation to cytotoxicity)
IT Skin-infecting fungi
(infections from; substituted tetracycline compds. as synergistic antifungal agents in relation to cytotoxicity)
IT Mucor
(mucormycosis from; substituted tetracycline compds. as synergistic antifungal agents in relation to cytotoxicity)
IT Mycosis
(mycetoma; substituted tetracycline compds. as synergistic antifungal agents in relation to cytotoxicity)
IT Oomycetes
(oomycosis from; substituted tetracycline compds. as synergistic antifungal agents in relation to cytotoxicity)
IT Paecilomyces
(paecilimycosis from; substituted tetracycline compds. as synergistic antifungal agents in relation to cytotoxicity)
IT Paracoccidioides brasiliensis
(paracoccidioidomycosis from; substituted tetracycline compds. as synergistic antifungal agents in relation to cytotoxicity)
IT Penicillium
(penicilliosis from; substituted tetracycline compds. as synergistic antifungal agents in relation to cytotoxicity)
IT Rhinosporidium
(rhinosporidiosis from; substituted tetracycline compds. as synergistic antifungal agents in relation to cytotoxicity)
IT Aspergillus nidulans
Athlete's foot
Candida albicans
Candida dubliniensis
Candida glabrata
Candida guilliermondii
Candida krusei
Candida lusitaniae
Candida neoformans
Candida parapsilosis
Candida tropicalis
Cytotoxicity
Human
Issatchenkia orientalis
Mammalia

Mycosis
(substituted tetracycline compds. as synergistic antifungal agents in relation to cytotoxicity)

IT Polyenes
Tetracyclines
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(substituted tetracycline compds. as synergistic antifungal agents in relation to cytotoxicity)

IT Drug interactions
Fungicides
(synergistic; substituted tetracycline compds. as synergistic antifungal agents in relation to cytotoxicity)

IT Anti-inflammatory agents
(tetracyclines; substituted tetracycline compds. as synergistic antifungal agents in relation to cytotoxicity)

IT 389624-44-6P
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(substituted tetracycline compds. as synergistic antifungal agents in relation to cytotoxicity)

IT 263761-05-3P 351336-94-2P 380435-63-2P 389623-77-2P 389624-48-0P
389624-49-1P 389624-67-3P 389624-88-8P 460068-27-3P 460069-92-5P
460072-21-3P 460073-05-6P 460073-43-2P 460073-62-5P 460073-68-1P
460073-82-9P 460074-13-9P 460074-36-6P 460074-56-0P 460074-58-2P
460074-69-5P
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(substituted tetracycline compds. as synergistic antifungal agents in relation to cytotoxicity)

IT 564-25-0 1397-89-3, Amphotericin B 5995-55-1 31642-30-5 35689-65-7
113164-67-3 120793-45-5 146253-75-0 146278-03-7 151922-17-7
161321-34-2 161452-36-4 186759-47-7 186759-51-3 186759-53-5
186759-61-5 220620-09-7 233585-94-9 233585-95-0 233586-04-4
233586-06-6 233586-11-3 233586-12-4 263760-96-9 263760-99-2
263761-02-0 263761-08-6 295356-11-5 295356-12-6 330627-21-9
330627-24-2 330627-27-5 365277-01-6 365277-03-8 365277-07-2
365277-13-0 365277-14-1 365277-16-3 365277-23-2
365277-28-7 365277-29-8 365277-35-6 365277-36-7 365277-38-9
365277-39-0 365277-40-3 365277-42-5
365277-43-6 365277-46-9 365277-47-0 365277-48-1
365277-49-2 365277-50-5 365277-51-6 365277-52-7 365277-53-8
365277-54-9 365277-55-0 365277-56-1 365277-60-7 365277-61-8
365277-62-9 365277-63-0 365277-65-2 374748-06-8 380435-65-4
380435-74-5 380435-76-7 389081-56-5 389081-58-7 389081-59-8
389081-61-2 389081-63-4 389081-67-8 389081-68-9 389081-77-0
389081-78-1 389081-82-7 389081-85-0 389139-10-0 389139-12-2
389139-16-6 389139-17-7 389139-19-9 389139-20-2 389139-21-3
389139-22-4 389139-23-5 389139-24-6 389139-26-8 389139-27-9
389139-28-0 389139-31-5 389139-32-6 389139-33-7 389139-41-7
389139-43-9 389139-45-1 389139-46-2 389139-48-4 389139-49-5
389139-50-8 389139-51-9 389139-53-1 389139-54-2 389139-55-3
389139-56-4 389139-58-6 389139-59-7 389139-61-1 389139-62-2
389139-63-3 389139-64-4 389139-65-5 389139-66-6 389139-67-7
389139-68-8 389139-69-9 389139-70-2 389139-71-3 389139-72-4
389139-73-5 389139-75-7 389139-76-8 389139-78-0 389139-79-1
389139-81-5 389139-82-6 389139-83-7 389139-85-9 389139-86-0
389139-87-1 389139-88-2 389139-89-3 389139-90-6 389139-91-7
389139-92-8 389139-93-9 389139-94-0 389139-95-1 389139-96-2
389139-97-3 389139-98-4 389139-99-5 389140-00-5 389140-01-6

389140-02-7 389140-03-8 389570-51-8 389623-72-7 389623-82-9
389623-84-1 389623-86-3 389623-88-5 389623-89-6 389623-90-9
389623-91-0 389623-95-4 389623-97-6 389623-99-8 389624-05-9
389624-06-0 389624-08-2 389624-09-3 389624-13-9 389624-14-0
389624-18-4 389624-19-5 389624-20-8 389624-21-9 389624-22-0
389624-24-2 389624-31-1 389624-32-2 389624-33-3 389624-34-4
389624-36-6 389624-38-8 389624-39-9 389624-40-2 389624-41-3
389624-42-4 389624-43-5 389624-47-9 389624-51-5 389624-52-6
389624-53-7 389624-54-8 389624-55-9 389624-56-0 389624-57-1
389624-59-3 389624-60-6 389624-61-7 389624-64-0 389624-65-1
389624-66-2 389624-68-4 389624-69-5 389624-70-8 389624-71-9
389624-72-0 389624-73-1 389624-74-2 389624-75-3 389624-76-4
389624-77-5 389624-78-6 389624-79-7 389624-80-0 389624-81-1
389624-82-2 389624-83-3 389624-85-5 389624-86-6 389624-87-7
389624-89-9 389624-90-2 389624-91-3 389624-92-4 389624-93-5
389624-94-6 389624-97-9 389624-98-0 389624-99-1 389625-01-8
389625-02-9 389625-03-0 389625-04-1 389625-06-3 389625-07-4
389625-09-6 389625-09-6 389625-10-9 389625-11-0 389625-12-1
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(substituted tetracycline compds. as synergistic antifungal agents in relation to cytotoxicity)

IT 459809-44-0 459809-45-1 459809-46-2 459809-47-3 459809-48-4
459809-49-5 459809-50-8 459809-51-9 459809-52-0 459809-53-1
459809-54-2 459809-55-3 459809-56-4 459809-57-5 459809-61-1
459809-63-3 459809-65-5 459809-66-6 459809-67-7 459809-68-8
459809-70-2 459809-72-4 459809-74-6 459809-76-8 459809-77-9
459809-82-6 459809-88-2 459809-91-7 459809-93-9 459809-94-0
459809-95-1 459809-96-2 459809-97-3 459809-98-4 459809-99-5
459810-00-5 459810-01-6 459810-02-7 459810-04-9 459810-07-2
459810-08-3 460068-26-2 460068-28-4 460068-29-5 460068-30-8
460068-31-9 460068-32-0 460068-33-1 460068-34-2 460068-35-3
460068-36-4 460068-37-5 460068-38-6 460068-39-7 460068-40-0
460068-41-1 460068-42-2 460068-43-3 460068-44-4 460068-45-5
460068-46-6 460068-47-7 460068-48-8 460068-49-9 460068-50-2
460068-51-3 460068-52-4 460068-53-5 460068-54-6 460068-55-7
460068-56-8 460068-57-9 460068-58-0 460068-59-1 460068-60-4
460068-61-5 460068-62-6 460068-63-7 460068-64-8 460068-65-9
460068-66-0 460068-67-1 460068-68-2 460068-69-3 460068-70-6
460068-71-7 460068-72-8 460068-73-9 460068-74-0 460068-75-1
460068-76-2 460068-77-3 460068-78-4 460068-79-5 460068-80-8
460068-81-9 460068-82-0 460068-83-1 460068-84-2 460068-85-3
460068-86-4 460068-87-5 460068-88-6 460068-89-7 460068-90-0
460068-91-1 460068-92-2 **460068-93-3**
460068-94-4 460068-95-5 460068-96-6 460068-97-7
460068-99-9 460069-25-4 460069-34-5 460069-38-9 460069-65-2
460069-70-9 460069-76-5 460069-89-0 460069-96-9 460069-99-2
460070-02-4 460070-03-5 460070-34-2 460070-44-4 460070-53-5
460070-61-5 460070-66-0 460070-73-9 460070-76-2 460070-79-5
460070-83-1 460070-92-2 460070-95-5 460071-02-7 460071-04-9
460071-06-1 460071-09-4 460071-12-9 460071-14-1 460071-17-4
460071-19-6 460071-23-2 460071-29-8 460071-31-2 460071-33-4
460071-37-8 460071-66-3 460071-69-6 460071-80-1 460071-83-4
460071-87-8 460071-89-0 460071-91-4 460071-93-6 460071-95-8
460071-97-0 460071-99-2 460072-01-9 460072-03-1 460072-05-3
460072-07-5 460072-09-7 460072-10-0 460072-12-2 460072-15-5
460072-17-7 460072-19-9 460072-25-7 460072-27-9 460072-28-0
460072-29-1 460072-30-4 460072-31-5 460072-33-7 460072-36-0
460072-38-2 460072-40-6 460072-43-9 460072-45-1 460072-47-3
460072-49-5 460072-51-9 460072-53-1 460072-55-3 460072-57-5
460072-59-7 460072-61-1 460072-63-3 460072-65-5 460072-68-8
460072-70-2 460072-73-5 460072-75-7 460072-78-0 460072-80-4
460072-82-6 460072-86-0 460072-89-3 460072-91-7 460072-93-9

460072-99-5 460073-01-2 460073-03-4 460073-07-8 460073-09-0
460073-11-4 460073-15-8 460073-17-0 460073-21-6 460073-22-7
460073-23-8 460073-25-0 460073-27-2 460073-29-4 460073-31-8
460073-33-0 460073-35-2 460073-37-4 460073-40-9 460073-41-0
460073-45-4 460073-47-6 **460073-49-8** 460073-51-2
460073-53-4 **460073-55-6** 460073-58-9 460073-60-3
460073-64-7 460073-66-9 460073-70-5 460073-72-7 460073-74-9
460073-76-1
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(substituted tetracycline compds. as synergistic antifungal agents in relation to cytotoxicity)

IT 460073-78-3 460073-80-7 460073-84-1 460073-86-3 460073-88-5
460073-90-9 460073-92-1 460073-94-3 460073-96-5 460073-98-7
460074-00-4 460074-02-6 460074-04-8 460074-06-0 460074-09-3
460074-11-7 460074-15-1 460074-17-3 460074-19-5 460074-21-9
460074-23-1 460074-26-4 460074-28-6 460074-30-0 460074-32-2
460074-34-4 460074-38-8 460074-40-2 460074-42-4 460074-44-6
460074-46-8 460074-48-0 460074-50-4 460074-52-6 460074-54-8
460074-60-6 460074-62-8 460074-64-0 460074-66-2 460074-68-4
460074-71-9 460074-73-1 460074-75-3 460074-77-5 460074-79-7
460074-81-1 460074-83-3 460074-85-5 460074-87-7 460074-89-9
460074-91-3 460074-93-5 460074-95-7 460074-97-9 460074-99-1
460075-04-1 460075-06-3 460075-08-5 460075-10-9 460075-12-1
460075-14-3 460075-62-1 460076-23-7 460082-61-5 460082-62-6
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(substituted tetracycline compds. as synergistic antifungal agents in relation to cytotoxicity)

IT 74-99-7, Propyne 78-84-2, Isobutyraldehyde 103-55-9, N'-Benzyl-N,N-dimethylethylenediamine 103-76-4, 1-Piperazineethanol 111-30-8, Glutaraldehyde 122-78-1, Phenylacetaldehyde 622-77-5, Benzylcyanamide 808-26-4, Sancycline 871-84-1, 1,7-Octadiyne 914-00-1, Methacycline 4199-35-3 27329-70-0, 2-Formylfuran-5-boronic acid 50696-61-2, Cyclohexenylacetylene 55552-70-0, 3-Furanylboronic acid 107099-99-0, 2,5-Dimethoxyphenylboronic acid 128796-39-4, 4-Trifluoromethylphenylboronic acid 144025-03-6, 2,4-Difluorophenylboronic acid 149104-90-5 149934-19-0 380435-62-1 389140-04-9 459810-03-8 460076-33-9 460076-36-2 460076-37-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(substituted tetracycline compds. as synergistic antifungal agents in relation to cytotoxicity)

IT 460076-34-0P 460076-35-1P 460076-38-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(substituted tetracycline compds. as synergistic antifungal agents in relation to cytotoxicity)

IT **365277-13-0**
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(substituted tetracycline compds. as synergistic antifungal agents in relation to cytotoxicity)

RN 365277-13-0 HCAPLUS
CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-9-[[4-(3-nitrophenyl)-2-thiazolyl]amino]-1,11-dioxo-, (4S,4aR,5S,5aR,6R,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L9 ANSWER 4 OF 7 HCAPLUS COPYRIGHT 2003 ACS
AN 2002:716027 HCAPLUS
DN 137:244597
TI Substituted tetracycline compounds as antifungal agents
IN Draper, Michael; **Nelson, Mark L.**
PA **Paratek Pharmaceuticals, Inc., USA**
SO PCT Int. Appl., 71 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K
CC 10-5 (Microbial, Algal, and Fungal Biochemistry)
Section cross-reference(s): 1, 5, 26
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002072022	A2	20020919	WO 2002-US7502	20020314

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2001-275948P P 20010314
OS MARPAT 137:244597
AB Methods and compns. for treating fungal assocd. disorders in subjects are discussed. The method includes contacting the fungus with an effective amt. of a substituted tetracycline compd., such that the growth of said fungus is inhibited.
ST tetracycline antifungal agent
IT Actinomyces
(actinomycosis from; substituted tetracycline compds. as antifungal agents in relation to cytotoxicity)
IT Fungicides
(agrochem.; substituted tetracycline compds. as antifungal agents in relation to cytotoxicity)
IT Aspergillus
(aspergillosis from; substituted tetracycline compds. as antifungal agents in relation to cytotoxicity)
IT Blastomyces
Mycosis
(blastomycosis, North American; substituted tetracycline compds. as antifungal agents in relation to cytotoxicity)
IT Blastomyces
Mycosis
(blastomycosis; substituted tetracycline compds. as antifungal agents

in relation to cytotoxicity)
IT Candida albicans
(candidiasis from; substituted tetracycline compds. as antifungal agents in relation to cytotoxicity)
IT Drug delivery systems
(carriers; substituted tetracycline compds. as antifungal agents in relation to cytotoxicity)
IT Skin, disease
(chromoblastomycosis; substituted tetracycline compds. as antifungal agents in relation to cytotoxicity)
IT Mycosis
(coccidioidomycosis; substituted tetracycline compds. as antifungal agents in relation to cytotoxicity)
IT Tinea (skin disease)
(cruris; substituted tetracycline compds. as antifungal agents in relation to cytotoxicity)
IT Cryptococcus neoformans
(cryptococcosis from; substituted tetracycline compds. as antifungal agents in relation to cytotoxicity)
IT Lymphatic system
(disease, epizootic lymphangitis; substituted tetracycline compds. as antifungal agents in relation to cytotoxicity)
IT Toxicity
(drug, immunosuppression from, fungal infections in; substituted tetracycline compds. as antifungal agents in relation to cytotoxicity)
IT Entomophthorales
(entomophthoromycosis from; substituted tetracycline compds. as antifungal agents in relation to cytotoxicity)
IT Histoplasma farciminosum
(epizootic lymphangitis from; substituted tetracycline compds. as antifungal agents in relation to cytotoxicity)
IT Immunosuppression
(from chemotherapy, fungal infections in; substituted tetracycline compds. as antifungal agents in relation to cytotoxicity)
IT AIDS (disease)
Immunodeficiency
(fungal infections in; substituted tetracycline compds. as antifungal agents in relation to cytotoxicity)
IT Disease, plant
(fungal; substituted tetracycline compds. as antifungal agents in relation to cytotoxicity)
IT Geotrichum candidum
(geotrichosis from; substituted tetracycline compds. as antifungal agents in relation to cytotoxicity)
IT Chemotherapy
(immunosuppression from, fungal infections in; substituted tetracycline compds. as antifungal agents in relation to cytotoxicity)
IT Histoplasma capsulatum
(infection with; substituted tetracycline compds. as antifungal agents in relation to cytotoxicity)
IT Skin-infecting fungi
(infections from; substituted tetracycline compds. as antifungal agents in relation to cytotoxicity)
IT Mucor
(mucormycosis from; substituted tetracycline compds. as antifungal agents in relation to cytotoxicity)
IT Mycosis
(mycetoma; substituted tetracycline compds. as antifungal agents in relation to cytotoxicity)
IT Oomycetes
(oomycosis from; substituted tetracycline compds. as antifungal agents in relation to cytotoxicity)
IT Paecilomyces

(paecilimycosis from; substituted tetracycline compds. as antifungal agents in relation to cytotoxicity)
IT Paracoccidioides brasiliensis
(paracoccidioidomycosis from; substituted tetracycline compds. as antifungal agents in relation to cytotoxicity)
IT Penicillium
(penicilliosis from; substituted tetracycline compds. as antifungal agents in relation to cytotoxicity)
IT Rhinosporidium
(rhinosporidiosis from; substituted tetracycline compds. as antifungal agents in relation to cytotoxicity)
IT Athlete's foot
Candida
Candida albicans
Candida dubliniensis
Candida glabrata
Candida guilliermondii
Candida krusei
Candida lusitaniae
Candida neoformans
Candida parapsilosis
Candida tropicalis
Cytotoxicity
Fungicides
Human
Mammalia
Mycosis
(substituted tetracycline compds. as antifungal agents in relation to cytotoxicity)
IT Tetracyclines
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(substituted tetracycline compds. as antifungal agents in relation to cytotoxicity)
IT 460072-70-2
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(a csubstituted tetracycline compds. as antifungal agents in relation to cytotoxicity)
IT 31642-30-5 113164-67-3 161452-36-4 233585-94-9 233585-95-0
233586-04-4 233586-06-6 233586-12-4 330627-29-7 351336-94-2
365277-14-1 365277-36-7 **365277-88-9** 380435-74-5
380435-76-7 389139-17-7 389139-27-9 389139-31-5 389139-33-7
389139-41-7 389139-43-9 389139-45-1 389139-49-5 389139-56-4
389139-64-4 389139-72-4 389139-73-5 389139-74-6 389139-75-7
389139-76-8 389139-80-4 389139-87-1 389139-90-6 389139-91-7
389623-86-3 389623-88-5 389623-89-6 389623-90-9 389623-96-5
389623-99-8 389624-06-0 389624-08-2 389624-09-3 389624-13-9
389624-18-4 389624-19-5 389624-20-8 389624-21-9 389624-33-3
389624-36-6 389624-38-8 389624-39-9 389624-41-3 389624-42-4
389624-43-5 389624-48-0 389624-64-0 389624-65-1 389624-67-3
389624-75-3 389624-76-4 389624-77-5 389624-78-6 389624-96-8
389625-11-0 459809-54-2 459809-55-3 459809-63-3 459809-81-5
459809-94-0 459809-99-5 459810-05-0 459810-08-3 460068-29-5
460068-30-8 460068-39-7 460068-40-0 460068-43-3 460068-44-4
460068-48-8 460068-49-9 460068-60-4 460068-72-8 460068-80-8
460068-84-2 460068-85-3 460068-86-4 460068-87-5 460068-88-6
460068-90-0 460069-34-5 460069-38-9 460071-97-0 460071-99-2
460072-10-0 460072-78-0 460072-80-4 460073-29-4 460073-37-4
460073-68-1 460074-28-6 460074-52-6 460074-60-6 460074-73-1
460082-75-1 460082-77-3 460082-81-9 460082-82-0 460082-83-1
460082-84-2 460082-85-3 460082-86-4 460082-87-5 460082-88-6
460082-89-7 460082-90-0 460082-91-1

RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(substituted tetracycline compds. as antifungal agents in relation to cytotoxicity)

IT 693-02-7, 1-Hexyne 808-26-4, Sancycline 85199-06-0, 2,5-Dimethylphenylboronic acid 389139-46-2, 9-(4-Fluorophenylethynyl)minocycline 389140-04-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(substituted tetracycline compds. as antifungal agents in relation to cytotoxicity)

IT 389139-70-2P, 9-(4'-Fluorophenylethyl)-Minocycline 460082-93-3P 460082-94-4P, 9-(2',5'-Dimethylphenyl)minocycline
RL: SPN (Synthetic preparation); PREP (Preparation)
(substituted tetracycline compds. as antifungal agents in relation to cytotoxicity)

IT **365277-14-1**
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(substituted tetracycline compds. as antifungal agents in relation to cytotoxicity)

RN 365277-14-1 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-9-[(5-methyl-4-phenyl-2-thiazolyl)amino]-1,11-dioxo-, (4S,4aR,5S,5aR,6R,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L9 ANSWER 5 OF 7 HCAPLUS COPYRIGHT 2003 ACS

AN 2002:51420 HCAPLUS

DN 136:102232

TI Preparation of 7-substituted tetracycline derivatives for pharmaceutical use as antibacterial agents

IN **Nelson, Mark L.**; **Frechette, Roger**; Viski, Peter; **Ismail, Mohamed**; **Bowser, Todd**; Bhatia, Beena; Messersmith, David; McIntyre, Laura; Koza, Darrell; Rennie, Glen; Sheahan, Paul; Hawkins, Paul; Verma, Atul; Warchol, Tad; Bandarage, Upul

PA Trustees of **Tufts** College, USA; **Paratek Pharmaceuticals, Inc.**

SO PCT Int. Appl., 97 pp.
CODEN: PIXXD2

DT Patent

LA English

IC ICM C07C237-00

CC 26-6 (Biomolecules and Their Synthetic Analogs)
Section cross-reference(s): 10

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002004407	A2	20020117	WO 2001-US20766	20010629
WO 2002004407	A3	20020404		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAI US 2000-216760P P 20000707
US 2001-275576P P 20010313

OS MARPAT 136:102232

GI



I

AB 7-Substituted tetracycline derivs., such as I [R7 = NO2, alkyl, alkenyl, alkynyl, aryl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, arylalkyl, amino, arylalkenyl, arylalkynyl, aminoalkyl, etc.], were prepd. for therapeutic use as antibacterial agents. Thus, 7-phenylsancycline I (R7 = Ph) was prepd. in 42% yield by arom. coupling reaction of 7-iodosancycline I (R7 = iodo) with PhB(OH)2 using Pd(OAc)2 and Na2CO3 in MeOH under an argon atm. at r.t. for 2 h. The prepd. tetracycline derivs. were tested for antibacterial activity against Escherichia coli, Enterococcus hirae, and Staphylococcus aureus.

ST tetracycline deriv prepn antibacterial agent; sancycline deriv prepn antibacterial agent

IT Antibacterial agents
(prepn. of 7-substituted tetracycline derivs. for pharmaceutical use as antibacterial agents)

IT 263761-01-9P 389624-24-2P 389624-36-6P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of 7-substituted tetracycline derivs. for pharmaceutical use as antibacterial agents)

IT 263760-96-9P 263760-98-1P 263760-99-2P 263761-02-0P
365277-42-5P 365277-44-7P 365277-45-8P 374748-06-8P
380435-62-1P 380435-63-2P 380435-65-4P 380435-76-7P 389623-67-0P
389623-72-7P 389623-74-9P 389623-77-2P 389623-80-7P 389623-82-9P
389623-84-1P 389623-86-3P 389623-88-5P 389623-89-6P 389623-90-9P
389623-91-0P 389623-93-2P 389623-95-4P 389623-96-5P 389623-97-6P
389623-98-7P 389623-99-8P 389624-00-4P 389624-01-5P 389624-02-6P
389624-03-7P 389624-04-8P 389624-05-9P 389624-06-0P 389624-07-1P
389624-08-2P 389624-09-3P 389624-10-6P 389624-11-7P 389624-12-8P
389624-13-9P 389624-14-0P 389624-15-1P 389624-16-2P 389624-17-3P
389624-18-4P 389624-19-5P 389624-20-8P 389624-21-9P 389624-22-0P
389624-23-1P 389624-25-3P 389624-26-4P 389624-27-5P 389624-28-6P
389624-29-7P 389624-30-0P 389624-31-1P 389624-32-2P 389624-33-3P
389624-34-4P 389624-35-5P 389624-37-7P 389624-38-8P 389624-39-9P
389624-40-2P 389624-41-3P 389624-42-4P 389624-43-5P 389624-44-6P

389624-45-7P 389624-46-8P 389624-47-9P 389624-48-0P 389624-49-1P
389624-50-4P 389624-51-5P 389624-52-6P 389624-53-7P 389624-54-8P
389624-55-9P 389624-56-0P 389624-57-1P 389624-58-2P 389624-59-3P
389624-60-6P 389624-61-7P 389624-62-8P 389624-63-9P 389624-64-0P
389624-65-1P 389624-66-2P 389624-67-3P 389624-68-4P 389624-69-5P
389624-70-8P 389624-71-9P 389624-72-0P 389624-73-1P 389624-74-2P
389624-75-3P 389624-76-4P 389624-77-5P 389624-78-6P 389624-79-7P
389624-80-0P 389624-81-1P 389624-82-2P 389624-83-3P 389624-84-4P
389624-85-5P 389624-86-6P 389624-87-7P 389624-88-8P 389624-89-9P
389624-90-2P 389624-91-3P 389624-92-4P 389624-93-5P 389624-94-6P
389624-95-7P 389624-96-8P 389624-97-9P 389624-98-0P 389624-99-1P
389625-00-7P 389625-01-8P 389625-02-9P 389625-03-0P 389625-04-1P
389625-05-2P 389625-06-3P 389625-07-4P 389625-08-5P 389625-09-6P
389625-10-9P 389625-11-0P 389625-12-1P 389625-13-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 7-substituted tetracycline derivs. for pharmaceutical use as antibacterial agents)

IT 98-80-6 623-47-2 808-26-4 871-84-1, 1,7-Octadiyne 1118-68-9
1679-18-1 1765-93-1 5679-00-5 7223-38-3 93501-84-9 127972-02-5
389625-14-3

RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of 7-substituted tetracycline derivs. for pharmaceutical use as antibacterial agents)

IT 113164-67-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of 7-substituted tetracycline derivs. for pharmaceutical use as antibacterial agents)

IT **365277-42-5P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 7-substituted tetracycline derivs. for pharmaceutical use as antibacterial agents)

RN 365277-42-5 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-7-[[4-(3-nitrophenyl)-2-thiazolyl]amino]-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L9 ANSWER 6 OF 7 HCAPLUS COPYRIGHT 2003 ACS

AN 2001:747739 HCAPLUS

DN 135:288637

TI Preparation of 7-and 9-carbamate, urea, thiourea, thiocarbamate, and heteroaryl-amino substituted tetracycline derivatives for pharmaceutical

use as antibiotics
IN **Nelson, Mark L.; Levy, Stuart B.; Prechette, Roger; Bowser, Todd E.; Ismail, Mohamed Y.**
PA Trustees of **Tufts** College, USA
SO PCT Int. Appl., 88 pp.
CODEN: PIXXD2
DT Patent
LA English
IC C07C271-30; C07C275-40; C07C271-58; C07C335-20; C07C235-84; C07D277-42; A61K031-65
CC 26-6 (Biomolecules and Their Synthetic Analogs)
Section cross-reference(s): 10
FAN.CNT 9

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001074761	A1	20011011	WO 2001-US10342	20010331
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2002103171	A1	20020801	US 2001-823884	20010330
EP 1272459	A1	20030108	EP 2001-924508	20010330
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2002128237	A1	20020912	US 2001-882273	20010615
US 2002147182	A1	20021010	US 2001-895796	20010629
US 6500812	B2	20021231		
PRAI US 2000-193879P	P	20000331		
US 2000-193972P	P	20000331		
US 2001-280367P	P	20010329		
US 1999-154701P	P	19990914		
US 2000-204158P	P	20000515		
US 2000-212030P	P	20000616		
US 2000-212139P	P	20000616		
US 2000-212471P	P	20000616		
WO 2000-US16672	W	20000616		
US 2000-216580P	P	20000707		
WO 2001-US10342	W	20010331		

OS MARPAT 135:288637
GI



I

AB Tetracycline derivs., such as I [R5 = H, OH, acyloxy, etc.; R6 = H, Me, alkyl, etc.; R7, R9 = arylamino, urea, thiourea, carbamate, thiocarbamate, etc.; R8 = H, alkyl, alkenyl, alkynyl, aryl, alkoxy, alkylthio, etc.], were prepd. for pharmaceutical use as antibiotics. Thus, doxycycline deriv. I (R5 = OH, R6 = Me, R7 = R8 = H, R9 = 1-naphthylaminocarbonylamino) was prepd. by nitration of doxycycline with

potassium nitrate, Pd/C catalyzed hydrogenation of the nitrate to form 9-aminodoxycycline I (R5 = OH, R6 = Me, R7 = R8 = H, R9 = NH2) followed by formation of the desired urea by reaction of 9-aminodoxycycline with 1-naphthylisocyanate. The prepd. tetracycline derivs. were tested for efficacy against common bacterial strains, such as E. coli, S. aureus, E. hirae, and E. faecalis.

ST tetracycline deriv prepn antibiotic; doxycycline deriv prepn antibiotic; minocycline deriv prepn antibiotic; sancycline deriv prepn antibiotic; carbamate tetracycline deriv prepn antibiotic; urea tetracycline deriv prepn antibiotic; thiourea tetracycline deriv prepn antibiotic; thiocarbamate tetracycline deriv prepn antibiotic; amino tetracycline deriv prepn antibiotic; antibacterial agent tetracycline deriv prepn

IT Antibiotics
(anthracycline; prepn. of 7-and 9-carbamate, urea, thiourea, thiocarbamate, and heteroaryl-amino substituted tetracycline derivs. for pharmaceutical use as antibiotics)

IT Antibacterial agents
(prepn. of 7-and 9-carbamate, urea, thiourea, thiocarbamate, and heteroaryl-amino substituted tetracycline derivs. for pharmaceutical use as antibiotics)

IT 365277-08-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of 7-and 9-carbamate, urea, thiourea, thiocarbamate, and heteroaryl-amino substituted tetracycline derivs. for pharmaceutical use as antibiotics)

IT 161320-33-8P 161452-36-4P 161452-37-5P 365276-98-8P 365276-99-9P
365277-00-5P 365277-01-6P 365277-02-7P 365277-03-8P 365277-04-9P
365277-05-0P 365277-06-1P 365277-07-2P 365277-09-4P
365277-10-7P 365277-11-8P 365277-12-9P
365277-13-0P 365277-14-1P 365277-15-2P 365277-16-3P
365277-17-4P 365277-18-5P 365277-19-6P 365277-20-9P
365277-21-0P 365277-22-1P 365277-23-2P 365277-24-3P 365277-25-4P
365277-26-5P 365277-27-6P 365277-28-7P 365277-29-8P 365277-31-2P
365277-32-3P 365277-33-4P 365277-34-5P 365277-35-6P 365277-36-7P
365277-37-8P 365277-38-9P **365277-39-0P 365277-40-3P**
365277-41-4P 365277-42-5P 365277-43-6P
365277-44-7P 365277-45-8P 365277-46-9P 365277-47-0P 365277-48-1P
365277-49-2P 365277-50-5P 365277-51-6P 365277-52-7P 365277-53-8P
365277-54-9P 365277-55-0P 365277-56-1P 365277-57-2P 365277-58-3P
365277-59-4P 365277-60-7P 365277-61-8P 365277-62-9P 365277-63-0P
365277-64-1P 365277-65-2P **365277-66-3P** 365277-67-4P
365277-68-5P 365277-69-6P 365277-70-9P 365277-71-0P
365277-74-3P 365277-75-4P 365277-76-5P
365277-77-6P 365277-78-7P 365277-79-8P
365277-80-1P 365277-81-2P 365277-82-3P 365277-83-4P 365277-84-5P
365277-85-6P 365277-86-7P 365277-87-8P **365277-88-9P**
365277-89-0P 365277-90-3P 365277-91-4P 365277-92-5P 365277-93-6P
365277-94-7P 365277-95-8P 365277-96-9P 365277-97-0P
365277-98-1P 365277-99-2P 365278-00-8P
365278-01-9P 365278-02-0P 365278-03-1P
365278-04-2P 365278-05-3P 365278-06-4P 365278-07-5P
365278-08-6P 365278-09-7P 365278-10-0P 365278-11-1P 365278-12-2P
365278-13-3P 365278-14-4P 365278-15-5P 365280-21-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 7-and 9-carbamate, urea, thiourea, thiocarbamate, and heteroaryl-amino substituted tetracycline derivs. for pharmaceutical use as antibiotics)

IT 70-11-1 86-84-0 103-71-9, reactions 564-25-0 816-40-0 1118-68-9

1609-86-5 2114-00-3 2227-64-7 2632-13-5 7693-41-6 16588-69-5
16588-74-2 20412-38-8 24608-52-4 28920-43-6 38377-38-7
149934-19-0 199915-38-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of 7-and 9-carbamate, urea, thiourea, thiocarbamate, and heteroaryl-amino substituted tetracycline derivs. for pharmaceutical use as antibiotics)

IT 161321-34-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of 7-and 9-carbamate, urea, thiourea, thiocarbamate, and heteroaryl-amino substituted tetracycline derivs. for pharmaceutical use as antibiotics)

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Barden, T; JOURNAL OF MEDICINAL CHEMISTRY 1994, V37, P3205 HCAPLUS
(2) Levy, S; WO 9937306 A 1999 HCAPLUS
(3) Pfizer; WO 9634852 A 1996 HCAPLUS
(4) Rogalski, W; US 4024272 A 1977 HCAPLUS
(5) Sum Phaik-Eng; US 5401729 A 1995 HCAPLUS

IT **365277-10-7P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 7-and 9-carbamate, urea, thiourea, thiocarbamate, and heteroaryl-amino substituted tetracycline derivs. for pharmaceutical use as antibiotics)

RN 365277-10-7 HCAPLUS

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-9-[(4-phenyl-2-thiazolyl)amino]-, (4S,4aR,5S,5aR,6R,12aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L9 ANSWER 7 OF 7 HCAPLUS COPYRIGHT 2003 ACS

AN 1995:394745 HCAPLUS

DN 122:158792

TI Preparation of 9-[(N-substituted-glycyl)amido]-6-methyl(ene)-5-hydroxy-6-deoxytetracyclines as antibiotics

IN Lee, Ving Jick; Buckwalter, Brian Lee; Barden, Timothy Claude

PA American Cyanamid Co., USA

SO Eur. Pat. Appl., 48 pp.
CODEN: EPXXDW

DT Patent

LA English

IC ICM C07C237-26
ICS A61K031-65

CC 16-6 (Fermentation and Bioindustrial Chemistry)
Section cross-reference(s): 1

FAN.CNT 1

PATENT NO. KIND DATE APPLICATION NO. DATE

PI	EP 618190	A1	19941005	EP 1994-104690	19940324
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	US 5371076	A	19941206	US 1993-42302	19930402
	CA 2120374	AA	19941003	CA 1994-2120374	19940331
	JP 07138220	A2	19950530	JP 1994-85318	19940401
	US 5639742	A	19970617	US 1994-297464	19940829
PRAI	US 1993-42302		19930402		
OS	MARPAT 122:158792				
GI					



AB Title compds. [I; R = Me and R3 = H; RR3 = CH2; R1 = H, (un)substituted alkyl, -aryl, etc.; R2 = H, alkyl; W = (un)substituted amino] were prepd. Thus, I (R = Me, R1-R3 = H, W = NMe2) had MIC of 0.25 and 0.50 (units not given) against Escherichia coli UBMS 90-4 and Staphylococcus aureus UBMS 90-1, resp.

ST amidodeoxytetracycline prepn antibiotic; deoxytetracycline amido prepn antibiotic

IT Antibiotics
(prepn. of 9-[(N-substituted-glycyl)amido]-6-methyl(ene)-5-hydroxy-6-deoxytetracyclines as antibiotics)

IT 161320-23-6P 161320-24-7P 161320-25-8P 161320-26-9P 161320-27-0P
161320-28-1P 161320-29-2P 161320-30-5P 161320-31-6P 161320-32-7P
161320-33-8P 161320-34-9P 161320-35-0P 161320-36-1P 161320-37-2P
161320-38-3P 161320-39-4P 161320-40-7P 161320-41-8P 161320-42-9P
161320-43-0P 161320-44-1P 161320-45-2P 161320-46-3P 161320-47-4P
161320-48-5P 161320-49-6P 161320-50-9P 161320-51-0P 161320-52-1P
161320-53-2P 161320-54-3P 161320-55-4P 161320-56-5P 161320-57-6P
161320-58-7P 161320-59-8P 161320-60-1P 161320-61-2P 161320-62-3P
161320-63-4P 161320-64-5P 161320-65-6P 161320-66-7P 161320-67-8P
161320-68-9P 161320-69-0P 161320-70-3P 161320-71-4P 161320-72-5P
161320-73-6P 161320-74-7P 161320-75-8P 161320-76-9P 161320-77-0P
161320-78-1P 161320-79-2P 161320-80-5P 161320-81-6P 161320-82-7P
161320-83-8P 161320-84-9P 161320-85-0P 161320-86-1P 161320-87-2P
161320-88-3P 161320-89-4P 161320-90-7P 161320-91-8P 161320-92-9P
161320-93-0P 161320-94-1P 161320-95-2P 161320-96-3P 161320-97-4P
161320-98-5P 161320-99-6P 161321-00-2P 161321-01-3P 161321-02-4P
161321-03-5P 161321-04-6P 161321-05-7P 161321-06-8P 161321-07-9P
161321-08-0P 161321-09-1P 161321-10-4P 161321-11-5P
161321-12-6P 161321-13-7P 161321-14-8P 161321-15-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 9-[(N-substituted-glycyl)amido]-6-methyl(ene)-5-hydroxy-6-deoxytetracyclines as antibiotics)

IT 75-64-9, tert-Butylamine, reactions 78-81-9, Isobutylamine 79-04-9, Chloroacetyl chloride 100-46-9, Benzylamine, reactions 107-10-8, Propylamine, reactions 109-73-9, Butylamine, reactions 109-89-7, reactions 110-58-7, Amylamine 110-89-4, Piperidine, reactions 123-75-1, Pyrrolidine, reactions 124-40-3, Dimethylamine, reactions 147-85-3, L-Proline, reactions 563-76-8, 2-Bromopropionyl bromide

598-21-0, Bromoacetyl bromide 626-58-4, 4-MethylPiperidine 765-38-8, 2-Methylpyrrolidine 1676-90-0 2516-47-4, Cyclopropanemethanamine 3731-51-9, 2-Aminomethylpyridine 4530-20-5, N-(tert-Butoxycarbonyl)glycine 13726-84-6 17469-89-5, N,N-Dimethyl-L-phenylalanine 27757-85-3, 2-Thiophenemethylamine 35661-40-6 35661-60-0 53363-89-6, N-(tert-Butoxycarbonyl)-N-methyl-L-leucine 71989-20-3 71989-26-9 71989-38-3 86123-10-6, N-(9-Fluorenylmethoxycarbonyl)-D-phenylalanine 161321-34-2 161321-35-3 161321-36-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of 9-[(N-substituted-glycyl)amido]-6-methyl(ene)-5-hydroxy-6-deoxytetracyclines as antibiotics)

IT 161321-16-0P 161321-17-1P 161321-18-2P 161321-19-3P 161321-20-6P 161321-21-7P 161321-22-8P 161321-23-9P 161321-24-0P 161321-25-1P 161321-26-2P 161321-27-3P 161321-28-4P 161321-29-5P 161321-30-8P 161321-31-9P 161321-32-0P 161321-33-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of 9-[(N-substituted-glycyl)amido]-6-methyl(ene)-5-hydroxy-6-deoxytetracyclines as antibiotics)

IT **161321-08-0P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 9-[(N-substituted-glycyl)amido]-6-methyl(ene)-5-hydroxy-6-deoxytetracyclines as antibiotics)

RN 161321-08-0 HCAPLUS
CN 2H-1,2-Oxazine-2-propanoic acid, 4-[[9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]amino]tetrahydro-6-(hydroxymethyl)- (9CI) (CA INDEX NAME)



=> fil reg
FILE 'REGISTRY' ENTERED AT 17:20:09 ON 13 FEB 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 12 FEB 2003 HIGHEST RN 489395-53-1
DICTIONARY FILE UPDATES: 12 FEB 2003 HIGHEST RN 489395-53-1

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=> d ide can tot l3

L3 ANSWER 1 OF 50 REGISTRY COPYRIGHT 2003 ACS
RN 488819-23-4 REGISTRY
CN INDEX NAME NOT YET ASSIGNED
FS STEREOSEARCH
MF C32 H45 N5 O7
SR CA
LC STN Files: CAPLUS

Absolute stereochemistry.



1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

L3 ANSWER 2 OF 50 REGISTRY COPYRIGHT 2003 ACS
RN 488818-49-1 REGISTRY
CN INDEX NAME NOT YET ASSIGNED
FS STEREOSEARCH
MF C30 H40 N4 O7
SR CA
LC STN Files: CAPLUS

Absolute stereochemistry.



1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

L3 ANSWER 3 OF 50 REGISTRY COPYRIGHT 2003 ACS
RN 488818-48-0 REGISTRY
CN INDEX NAME NOT YET ASSIGNED
FS STEREOSEARCH
MF C31 H36 N4 O8
SR CA
LC STN Files: CAPLUS

Absolute stereochemistry.



1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

L3 ANSWER 4 OF 50 REGISTRY COPYRIGHT 2003 ACS
RN 488818-39-9 REGISTRY
CN INDEX NAME NOT YET ASSIGNED
FS STEREOSEARCH
MF C30 H40 N4 O8
SR CA
LC STN Files: CAPLUS

Absolute stereochemistry.



1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

L3 ANSWER 5 OF 50 REGISTRY COPYRIGHT 2003 ACS
RN 488818-36-6 REGISTRY
CN INDEX NAME NOT YET ASSIGNED
FS STEREOSEARCH
MF C31 H42 N4 O8
SR CA
LC STN Files: CAPLUS

Absolute stereochemistry.



1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

L3 ANSWER 6 OF 50 REGISTRY COPYRIGHT 2003 ACS
RN 488818-35-5 REGISTRY
CN INDEX NAME NOT YET ASSIGNED
FS STEREOSEARCH
MF C26 H32 N4 O7
SR CA
LC STN Files: CAPLUS

Absolute stereochemistry.



1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

L3 ANSWER 7 OF 50 REGISTRY COPYRIGHT 2003 ACS
RN 488818-33-3 REGISTRY
CN INDEX NAME NOT YET ASSIGNED
FS STEREOSEARCH
MF C27 H34 N4 O7
SR CA
LC STN Files: CAPLUS

Absolute stereochemistry.



1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

L3 ANSWER 8 OF 50 REGISTRY COPYRIGHT 2003 ACS
RN 488818-29-7 REGISTRY
CN INDEX NAME NOT YET ASSIGNED
FS STEREOSEARCH
MF C33 H38 N4 O7
SR CA
LC STN Files: CAPLUS

Absolute stereochemistry.



1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

L3 ANSWER 9 OF 50 REGISTRY COPYRIGHT 2003 ACS
RN 488818-24-2 REGISTRY
CN INDEX NAME NOT YET ASSIGNED
FS STEREOSEARCH
MF C32 H44 N4 O8
SR CA
LC STN Files: CAPLUS

Absolute stereochemistry.



1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

L3 ANSWER 10 OF 50 REGISTRY COPYRIGHT 2003 ACS
RN 488818-23-1 REGISTRY
CN INDEX NAME NOT YET ASSIGNED
FS STEREOSEARCH
MF C28 H36 N4 O7
SR CA
LC STN Files: CAPLUS

Absolute stereochemistry.



1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

L3 ANSWER 11 OF 50 REGISTRY COPYRIGHT 2003 ACS
RN 488818-22-0 REGISTRY
CN INDEX NAME NOT YET ASSIGNED

FS STEREOSEARCH
MF C28 H36 N4 O8
SR CA
LC STN Files: CAPLUS

Absolute stereochemistry.



1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

L3 ANSWER 12 OF 50 REGISTRY COPYRIGHT 2003 ACS
RN 488818-15-1 REGISTRY
CN INDEX NAME NOT YET ASSIGNED
FS STEREOSEARCH
MF C29 H38 N4 O8
SR CA
LC STN Files: CAPLUS

Absolute stereochemistry.



1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

L3 ANSWER 13 OF 50 REGISTRY COPYRIGHT 2003 ACS
RN 488817-34-1 REGISTRY
CN INDEX NAME NOT YET ASSIGNED
FS STEREOSEARCH
MF C27 H30 N4 O7 S
SR CA
LC STN Files: CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

L3 ANSWER 14 OF 50 REGISTRY COPYRIGHT 2003 ACS
RN 460082-89-7 REGISTRY
CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-[(1-methyl-4-piperidinyl)amino]-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C27 H34 N4 O7
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1962 TO DATE)
3 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:333118

REFERENCE 2: 137:244597

L3 ANSWER 15 OF 50 REGISTRY COPYRIGHT 2003 ACS
RN 460073-76-1 REGISTRY
CN 2-Naphthacenecarboxamide, 4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-9-[[1-(phenylmethyl)-4-piperidinyl]amino]-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C35 H43 N5 O7
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
2 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:244598

L3 ANSWER 16 OF 50 REGISTRY COPYRIGHT 2003 ACS
RN 460073-55-6 REGISTRY
CN 2-Naphthacenecarboxamide, 9-[butyl(1-methyl-4-piperidinyl)amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C31 H42 N4 O7
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
2 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:244598

L3 ANSWER 17 OF 50 REGISTRY COPYRIGHT 2003 ACS
RN 460073-49-8 REGISTRY
CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-7-[[1-(phenylmethyl)-4-piperidinyl]amino]-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C33 H38 N4 O7
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
2 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:244598

L3 ANSWER 18 OF 50 REGISTRY COPYRIGHT 2003 ACS
RN 460073-45-4 REGISTRY
CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-9-[[1-(phenylmethyl)-4-piperidinyl]amino]-, (4S,4aR,5S,5aR,6R,12aS)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C34 H40 N4 O8
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
2 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:244598

L3 ANSWER 19 OF 50 REGISTRY COPYRIGHT 2003 ACS
RN 460068-94-4 REGISTRY
CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-[[4-(3-nitrophenyl)-2-thiazolyl]amino]-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C30 H27 N5 O9 S
SR CA

LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
2 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:244598

L3 ANSWER 20 OF 50 REGISTRY COPYRIGHT 2003 ACS
RN 460068-93-3 REGISTRY
CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-9-[[4-(4-fluorophenyl)-2-thiazolyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C30 H27 F N4 O7 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1962 TO DATE)
3 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:333118

REFERENCE 2: 137:244598

L3 ANSWER 21 OF 50 REGISTRY COPYRIGHT 2003 ACS
RN 460068-91-1 REGISTRY
CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-9-[(4-tricyclo[3.3.1.13,7]dec-2-yl-2-thiazolyl)amino]-, (4S,4aR,5S,5aR,6R,12aS)-

(9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C35 H40 N4 O8 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:244598

L3 ANSWER 22 OF 50 REGISTRY COPYRIGHT 2003 ACS
RN 365278-05-3 REGISTRY
CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-7-[(4-tricyclo[3.3.1.13,7]dec-1-yl-2-thiazolyl)amino]-, (4S,4aR,5S,5aR,6R,12aS)-(9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C35 H40 N4 O8 S
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 135:288637

L3 ANSWER 23 OF 50 REGISTRY COPYRIGHT 2003 ACS
RN 365278-04-2 REGISTRY

CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-7-[(4-methyl-5-phenyl-2-thiazolyl)amino]-1,11-dioxo-, (4S,4aR,5S,5aR,6R,12aS)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C32 H32 N4 O8 S
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 135:288637

L3 ANSWER 24 OF 50 REGISTRY COPYRIGHT 2003 ACS
RN 365278-03-1 REGISTRY
CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-7-[[4-(3-nitrophenyl)-2-thiazolyl]amino]-1,11-dioxo-, (4S,4aR,5S,5aR,6R,12aS)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C31 H29 N5 O10 S
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 135:288637

L3 ANSWER 25 OF 50 REGISTRY COPYRIGHT 2003 ACS
RN 365278-02-0 REGISTRY
CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-7-[(4-phenyl-2-thiazolyl)amino]-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C30 H28 N4 O7 S
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 135:288637

L3 ANSWER 26 OF 50 REGISTRY COPYRIGHT 2003 ACS
RN 365278-01-9 REGISTRY
CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-7-[[4-(4-methoxyphenyl)-2-thiazolyl]amino]-6-methyl-1,11-dioxo-, (4S,4aR,5S,5aR,6R,12aS)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C32 H32 N4 O9 S
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 135:288637

L3 ANSWER 27 OF 50 REGISTRY COPYRIGHT 2003 ACS
RN 365278-00-8 REGISTRY
CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-7-[[4-(4-fluorophenyl)-2-thiazolyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aR,5S,5aR,6R,12aS)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C31 H29 F N4 O8 S
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 135:288637

L3 ANSWER 28 OF 50 REGISTRY COPYRIGHT 2003 ACS
RN 365277-99-2 REGISTRY
CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-7-[(4-ethyl-2-thiazolyl)amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aR,5S,5aR,6R,12aS)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH

MF C27 H30 N4 O8 S
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 135:288637

L3 ANSWER 29 OF 50 REGISTRY COPYRIGHT 2003 ACS
RN 365277-98-1 REGISTRY
CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-7-[(4-phenyl-2-thiazolyl)amino]-, (4S,4aR,5S,5aR,6R,12aS)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C31 H30 N4 O8 S
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 135:288637

L3 ANSWER 30 OF 50 REGISTRY COPYRIGHT 2003 ACS

RN 365277-88-9 REGISTRY
CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-9-[(4-tricyclo[3.3.1.13,7]dec-1-yl-2-thiazolyl)amino]-, (4S,4aR,5S,5aR,6R,12aS)-(9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C35 H40 N4 O8 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1962 TO DATE)
3 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:244597

REFERENCE 2: 135:288637

L3 ANSWER 31 OF 50 REGISTRY COPYRIGHT 2003 ACS
RN 365277-79-8 REGISTRY
CN 2-Naphthacenecarboxamide, 4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-9-[(4-tricyclo[3.3.1.13,7]dec-1-yl-2-thiazolyl)amino]-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C36 H43 N5 O7 S
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 135:288637

L3 ANSWER 32 OF 50 REGISTRY COPYRIGHT 2003 ACS
RN 365277-78-7 REGISTRY
CN 2-Naphthacenecarboxamide, 4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-[[4-(3-nitrophenyl)-2-thiazolyl]amino]-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C32 H32 N6 O9 S
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 135:288637

L3 ANSWER 33 OF 50 REGISTRY COPYRIGHT 2003 ACS
RN 365277-77-6 REGISTRY
CN 2-Naphthacenecarboxamide, 4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-[[4-(4-methoxyphenyl)-2-thiazolyl]amino]-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C33 H35 N5 O8 S
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 135:288637

L3 ANSWER 34 OF 50 REGISTRY COPYRIGHT 2003 ACS
RN 365277-76-5 REGISTRY
CN 2-Naphthacenecarboxamide, 4,7-bis(dimethylamino)-9-[[4-(4-fluorophenyl)-2-thiazolyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C32 H32 F N5 O7 S
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 135:288637

L3 ANSWER 35 OF 50 REGISTRY COPYRIGHT 2003 ACS
RN 365277-75-4 REGISTRY
CN 2-Naphthacenecarboxamide, 4,7-bis(dimethylamino)-9-[(4-ethyl-2-thiazolyl)amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C28 H33 N5 O7 S
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 135:288637

L3 ANSWER 36 OF 50 REGISTRY COPYRIGHT 2003 ACS
RN 365277-74-3 REGISTRY
CN 2-Naphthacenecarboxamide, 4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-9-[(4-phenyl-2-thiazolyl)amino]-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C32 H33 N5 O7 S
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 135:288637

L3 ANSWER 37 OF 50 REGISTRY COPYRIGHT 2003 ACS
RN 365277-66-3 REGISTRY
CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-9-[(4-phenyl-2-thiazolyl)amino]-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C30 H28 N4 O7 S
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1962 TO DATE)
3 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:333118

REFERENCE 2: 135:288637

L3 ANSWER 38 OF 50 REGISTRY COPYRIGHT 2003 ACS
RN 365277-43-6 REGISTRY
CN 4-Thiazolecarboxylic acid, 2-[[(5R,5aR,6S,6aR,7S,10aS)-9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C28 H30 N4 O10 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1962 TO DATE)
3 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:244598

REFERENCE 2: 135:288637

L3 ANSWER 39 OF 50 REGISTRY COPYRIGHT 2003 ACS
RN 365277-42-5 REGISTRY
CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-7-[[4-(3-nitrophenyl)-2-thiazolyl]amino]-1,11-dioxo-, (4S,4aS,5aR,12aS)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C30 H27 N5 O9 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1962 TO DATE)
4 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:244598

REFERENCE 2: 136:102232

REFERENCE 3: 135:288637

L3 ANSWER 40 OF 50 REGISTRY COPYRIGHT 2003 ACS
RN 365277-41-4 REGISTRY
CN 2-Naphthacenecarboxamide, 9-[(4-[1,1'-biphenyl]-4-yl-2-thiazolyl)amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aR,5S,5aR,6R,12aS)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C37 H34 N4 O8 S
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
2 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 135:288637

L3 ANSWER 41 OF 50 REGISTRY COPYRIGHT 2003 ACS
RN 365277-40-3 REGISTRY
CN 2-Naphthacenecarboxamide, 9-[[4-[4-(diethylamino)phenyl]-2-thiazolyl]amino]-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aR,5S,5aR,6R,12aS)-(9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C35 H39 N5 O8 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1962 TO DATE)
3 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:244598

REFERENCE 2: 135:288637

L3 ANSWER 42 OF 50 REGISTRY COPYRIGHT 2003 ACS
RN 365277-39-0 REGISTRY
CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-9-[(5-phenyl-2-thiazolyl)amino]-, (4S,4aR,5S,5aR,6R,12aS)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C31 H30 N4 O8 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1962 TO DATE)
3 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:244598

REFERENCE 2: 135:288637

L3 ANSWER 43 OF 50 REGISTRY COPYRIGHT 2003 ACS
RN 365277-18-5 REGISTRY
CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-9-[(5-methyl-4-tricyclo[3.3.1.13,7]dec-2-yl-2-thiazolyl)amino]-1,11-dioxo-, (4S,4aR,5S,5aR,6R,12aS)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH

MF C36 H42 N4 O8 S
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 135:288637

L3 ANSWER 44 OF 50 REGISTRY COPYRIGHT 2003 ACS
RN 365277-17-4 REGISTRY
CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-9-[[4-(4-fluorophenyl)-2-thiazolyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aR,5S,5aR,6R,12aS)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C31 H29 F N4 O8 S
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 135:288637

L3 ANSWER 45 OF 50 REGISTRY COPYRIGHT 2003 ACS
RN 365277-14-1 REGISTRY
CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-9-[(5-methyl-4-phenyl-2-thiazolyl)amino]-1,11-dioxo-, (4S,4aR,5S,5aR,6R,12aS)- (9CI) (CA INDEX

NAME)
FS STEREOSEARCH
MF C32 H32 N4 O8 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1962 TO DATE)
4 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:244598

REFERENCE 2: 137:244597

REFERENCE 3: 135:288637

L3 ANSWER 46 OF 50 REGISTRY COPYRIGHT 2003 ACS
RN 365277-13-0 REGISTRY
CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-9-[[4-(3-nitrophenyl)-2-thiazolyl]amino]-1,11-dioxo-, (4S,4aR,5S,5aR,6R,12aS)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C31 H29 N5 O10 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1962 TO DATE)
3 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 137:244598

REFERENCE 2: 135:288637

L3 ANSWER 47 OF 50 REGISTRY COPYRIGHT 2003 ACS
RN 365277-12-9 REGISTRY
CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-9-[[4-(4-methoxyphenyl)-2-thiazolyl]amino]-6-methyl-1,11-dioxo-, (4S,4aR,5S,5aR,6R,12aS)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C32 H32 N4 O9 S
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
2 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 135:288637

L3 ANSWER 48 OF 50 REGISTRY COPYRIGHT 2003 ACS
RN 365277-11-8 REGISTRY
CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-9-[(4-ethyl-2-thiazolyl)amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S,4aR,5S,5aR,6R,12aS)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C27 H30 N4 O8 S
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
2 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 135:288637

L3 ANSWER 49 OF 50 REGISTRY COPYRIGHT 2003 ACS
RN 365277-10-7 REGISTRY
CN 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-9-[(4-phenyl-2-thiazolyl)amino]-, (4S,4aR,5S,5aR,6R,12aS)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C31 H30 N4 O8 S
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 135:288637

L3 ANSWER 50 OF 50 REGISTRY COPYRIGHT 2003 ACS
RN 161321-08-0 REGISTRY
CN 2H-1,2-Oxazine-2-propanoic acid, 4-[[9-(aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,6,8,10a,11-pentahydroxy-5-methyl-10,12-dioxo-2-naphthacenyl]amino]tetrahydro-6-(hydroxymethyl)- (9CI) (CA INDEX NAME)
MF C30 H38 N4 O12
SR CA
LC STN Files: CA, CAPLUS, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 122:158792